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ABSTRACT
PETER C. NICHOLAS: Cerebral Metabolism of Ethanol-Derived Acetate:
A Metabolic Basis for Dependence?.
(Under the direction of Jeffrey M. Macdonald, Ph.D..)
Alcoholism is a tremendous health problem throughout the world. Ethanol is a
unique drug that is consumed in large quantities for pharmacologic effect, reaching
blood concentrations as high as 100mM. Ethanol is eliminated almost exclusively via
oxidation to acetate in the liver, and nearly all of the ethanol-derived acetate is released
into the blood where it travels to other organs, including the brain, for use as an
energy source. Thus ethanol directly alters metabolism in the liver, and causes the
production of large amounts of acetate which may serve as a substrate for brain, possibly
contributing to intoxication and dependence.
This dissertation describes two separate approaches to study the metabolic effects
of ethanol. First, 1H NMR-based metabolomic analysis of endogenous metabolites
revealed decreased lactate and alanine, and increased acetate and ketone bodies due
to ethanol. These results provided new insights regarding the effect of ethanol on
gluconeogenesis. In addition, we determined that ethyl glucuronide (EtG), a unique
metabolite of ethanol, produces a characteristic NMR signal. EtG is formed within
hours of ethanol dosing, and remains elevated during a 4 day binge exposure. The
antioxidant BHT appears to reduce formation of EtG during a 4 day exposure to
ethanol.
Our second approach used 13C-enriched tracers along with 13C NMR to measure
brain metabolism of ethanol-derived acetate. Our hypothesis was that cerebral metabolism
of acetate released from the liver during ethanol oxidation perturbs cerebral metabolism,
and thereby contributes to neuroadaptation associated with alcohol dependence and
withdrawal. Using a single dose of [2-13C] ethanol intragastrically, we found carbons
derived from ethanol are rapidly incorporated into brain amino acids glutamate, glu-
tamine, and GABA. Next, we investigated whether a 10 day exposure to ethanol would
increase cerebral utilization of acetate. We found that acetate metabolism was not in-
creased, most likely because transport into brain astrocytes was not increased. We did
find, however, that ethanol induced significant changes in metabolism of GABA, and
we speculate that this may reflect neuroadaptations that produce tolerance to ethanol.
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Chapter 1
Introduction and Background
As befits a dissertation in Biomedical Engineering, the studies described herein involve
the application of knowledge and techniques from the fields of physics, engineering,
chemistry, biochemistry, and biology. While it is beyond the scope of this work to
provide a complete account of all relevant aspects of these fields, the intent of this
introductory chapter is to provide an overview of the methods employed, a review of
the current literature, and the rationale for the work that is detailed in later chapters.
Before embarking on this task, however, a few words about the disease of alcoholism
are in order.
Alcoholism is a disease that produces enormous harm to both individual health and
society as a whole. Ethyl alcohol (ethanol, abbreviated EtOH) is a unique drug that
is (i) ubiquitous, (ii) legal to consume in most places, (iii) ingested in large quantities
compared to other pharmacologic agents, and therefore, (iv) metabolized to acetate
in the liver, producing sustained milimolar blood levels of this direct metabolite, (v)
capable of damaging multiple organs, including liver and brain. Due to (iii) and (iv), it
was natural to inquire about possible metabolic mechanisms for organ toxicity and al-
cohol addiction, leading to our initial metabolomic studies. Upon closer examination of
the literature, a hypothesis involving brain metabolism of ethanol-derived acetate pre-
sented itself as an attractive problem for study. Using carbon-13 ethanol as a metabolic
tracer, we monitored the brain’s metabolism of ethanol-derived acetate and studied the
effect of chronic ethanol ingestion on this process.
With these goals in mind, we turn to a description of NMR-based metabolomics.
1.1 Metabolomics
The emerging field of metabolomics represents an exciting new set of methods for the
characterization of biochemical systems and their response to environmental factors
such as diet and exposure to toxins. The approach involves quantification of small
molecules, coupled with various pattern recognition methods to extract meaningful in-
formation from the large data sets. (The complement of small molecules within an
organism is termed ’the metabolome’, hence the name metabolomics.) The goal is to
collect a relevant sample from the organism under study, obtain a ’metabolic finger-
print’ using techniques from analytical chemistry, and to apply mutivariate statistical
techniques to large numbers of samples (Nicholson et al., 1999). The many potential
applications of this technique include: (i) identification of inexpensive and non-invasive
diagnostic tests for various diseases, (ii) diagnosis of individuals likely to metabolize
medications differently than the population average, and (iii) in basic science stud-
ies, corroboration of genomic and proteomic data with measurements of endogenous
metabolites that are substrates for the genes in question.
Perhaps the strongest argument in favor of the metabolomic approach to diagnosis
or classification of individuals, as opposed to the search for individual ’biomarkers’ (i.e.
single molecules that are believed to be specific indicators of a particular disease or
phenotype) is that unique molecules are rarely present at the stage in which a disease is
preventable. For example, assays for Creatine Kinase Mb (CKMB) and cardiac isoforms
of certain other enzymes are extremely powerful diagnostic tools for heart attacks, but
only after one has occurred. There is presently no satisfactory biomarker for coronary
artery disease. Cholesterol levels and blood pressure have some predictive power, but
not enough to enable physicians to focus their efforts on preventing heart attacks in
those patients in which they are imminent. Thus, patients with suggestive symptoms
are referred for expensive and invasive tests in the form of cardiac catheterization. All
the while, it is reasonable to hypothesize that biochemical differences exist between
people who will eventually develop coronary artery disease and those who will remain
healthy.
Taking a different approach to the problem, Brindle et al. analyzed blood plasma
from patients undergoing cardiac catheterization. The investigators collected proton
NMR spectra of the plasma and used a supervised classification method to construct a
predictive model that enabled them to determine with impressive accuracy the presence
and severity of coronary artery occlusion based only on analysis of a blood sample.
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While there may be significant questions regarding the details of their methods (see
§5.6), the results of this study illustrate the power of a metabolomic approach to predict
the presence of a disease based on pattern recognition of the metabolic fingerprint,
where no single ”biomarker” is available.
With this tantalizing success in mind, we now delve into the details of the technique.
1.1.1 Analytical Methods for Metabolomics
Before discussing individual methods, it is useful to describe the attributes of an ideal
metabolomic measurement technique. First, the technique would be quantitative, pro-
viding reliable, independent measurements of all metabolites in a sample. Preferably,
the technique would allow simultaneous measurement of endogenous molecules and ex-
ogenous tracers (e.g. isotopes) to facilitate studies of metabolic flux. In addition, the
technique would be capable of analyzing samples at a rate of one every few minutes
or less, and would provide unambiguous data for which any post-processing would be
entirely automated so that full human effort could be devoted to interpretation of re-
sults, rather than the generation of results from raw data. As we will see, the methods
presently available are far from ideal, but each offers certain advantages and drawbacks.
1.1.2 Analytical Methods for Metabolomics: NMR
Nuclear magnetic resonance (NMR) spectroscopy is the preeminent tool for chemical
structure elucidation. Though it has a lower sensitivity to detection than techniques
such as mass spectrometry (MS) or liquid chromatography (LC), NMR spectroscopy
(NMRS) has several key advantages for quantitative analysis in metabolomics, most
notably its large dynamic range and minimal requirements for sample preparation.
In order to maintain the focus of this introductory chapter on the application of
NMRS as a tool for the study of ethanol metabolism and brain function, a brief review
of NMR physics, instrumentation, and associated issues is presented in Appendix A.
Instead, this section presents some examples of the use of NMRS in metabolomics.
The first example is a 700MHz proton spectrum of an extract from rat liver tissue
(Fig. 1.1A ). The second panel (B) shows an expanded view of the relatively un-
congested region between δ 0.9-2.0 ppm. Signals from several metabolites are clearly
resolved, and the high signal-to-noise ratio of this data is evident. Signals are assigned
on the basis of chemical shift (frequency), multiplicity and coupling constant. The
integrated intensity of each signal is directly proportional to concentration. Thus, in
3
Figure 1.1: 700MHz proton spectrum of perchloric acid extract of liver. The lower
panel (B) shows an expanded view of the signals from the methyl protons of several
metabolites. Abbreviations: Ace, acetate; Ala, alanine, 3HB, beta-hydroxybutyrate;
Ile, isoleucine; Leu, leucine; PG, propylene glycol; Thr, threonine; Val, Valine. Chemi-
cal structures for these molecules can be found in Appendix B.
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theory, we can observe and quantify signals from every proton-containing molecule that
was present in this animal’s liver.
In practice, two issues limit our ability to quantify certain compounds: sensitivity
and resolution/overlap. Using the most sensitive NMR spectrometer on campus at
the present time, a 700MHz Varian Inova system with a cold probe installed, the
detection threshold in a tissue extract is on the order of tens of µmol per kg tissue,
depending on the number of chemically equivalent protons attached. (More protons
produce greater signal, thus enabling the detection of smaller amounts of material.)
However, to determine a 50% reduction in this compound with confidence, its basal
level might need to be somewhat greater. Thus compounds that are present at very
low concentrations will go undetected in NMR analysis using current methods.
A number of approaches could lower the detection threshold. If the signal of interest
is large enough to be digitized, averaging more data will (eventually) yield adequate
signal-to-noise for quantification. If solubility of the compounds is not limiting, samples
may be pooled, and lyophilized extracts may be dissolved in smaller volumes of liquid
and analyzed in special NMR tubes, thus increasing the concentration perhaps 2-10
fold. Removing salts from the sample might improve the ability to tune the cold probe,
thus increasing the signal. However, even with great effort, the detection threshold will
remain in the hundreds of nM range. If molecules at this concentration are of interest,
one might consider concentrating the sample or isolating target molecules, but it might
be sensible to select a different technique.
The problem of spectral overlap is even more vexing than low sensitivity, because
it limits the quantification of compounds that are abundant enough to generate NMR
signals. Even if a compound is present at millimolar concentrations, if its NMR signals
overlap with those of other molecules, identification and unique quantification become
difficult, or, in many cases, impossible. (In other words, if A and B overlap, it is possible
to measure the sum A+B, but neither A nor B individually.)
Two methods can overcome the problem of overlapping NMR signals: (i) increase
the spectral resolution by using a higher field spectrometer, or (ii) decrease the width
of the signals by collapsing multiplets using a pulse sequence designed for this purpose
(e.g. (Viant, 2003). On the other hand, as we will see, it is sometimes possible to
classify individuals based on pattern recognition techniques that treat spectra as ab-
stract multivariate data without any knowledge of the underlying biochemical changes
that produce differences in spectra between groups. Though this approach sometimes
prevents insight into mechanisms responsible for disease, the ability to aid in certain di-
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agnoses may be extremely valuable even in the absence of a mechanistic understanding
of the processes that lead to disease.
As mentioned above, NMR spectroscopy offers impressive dynamic range. Modern
spectrometers boast 20-bit (220 ∼ 106) effective dynamic range, with full linearity of
response over this entire range. This figure applies to ’raw’ metabolomic samples such
as blood (serum and plasma) and urine. As we will see, the same is not true for mass
spectrometry.
1.1.3 Analytical Methods for Metabolomics: MS
Mass spectrometry (MS), like NMR, is a mature analytical technique that has recently
been applied to metabolomics. To be more precise, a family of hyphenated techniques
such as gas chromatography (GC-MS), liquid chromatography (LC-MS), and others
have been applied. In its most basic form, a mass spectrometer ionizes a sample, ac-
celerates the charged particles, and measures the mass/charge (m/z) ratio for the ions.
By measuring the mass of the parent ion precisely, the empirical formula can be in-
ferred. Thus, we come to the first limitation of MS: it cannot easily distinguish between
chemical isomers (Sumner et al., 2003). NMRS is inherently sensitive to chemical struc-
ture and therefore can distinguish many isomers easily. In addition, the ability of 13C
NMR spectroscopy to determine enrichment of each individual carbon atom within a
given molecule provides a powerful tool for the analysis of metabolic flux. The great
advantage of MS over NMR is the high sensitivity. Under ideal conditions, LC-MS
and GC-MS can measure pico-molar (10−12M) , and femto-molar (10−15M) concentra-
tions, respectively – 106 to 109 times lower than NMR can measure. So why would one
choose to use NMR? One answer lies in the phrase ”under ideal conditions”. Typical
metabolomic samples are far from ideal: they contain many classes of molecules (pro-
teins, lipids, glycoproteins, amino acids, sugars, nucleotides, etc. ) in concentrations
ranging from tens of millimolar down to a few molecules per mL. In order to make use
of sensitivity that enables detection down to 10−15M in a sample that contains some
molecules at 10−2M, a dynamic range of 1013 is required. In practice, the dynamic
range of MS is closer to 102-104, depending on the technique. The solution to this
problem involves on the one hand extraction, dilution, derivatization and other forms
of sample preparation, and on the other hand chromatographic separation to reduce
the amount of material being exposed to the detector at any time. These techniques
notwithstanding, issues such as differential ionization potential and competition or in-
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teraction between various metabolites in a single sample create a situation in which it
is very difficult to obtain quantitative data for a large set of samples.
Another reason to advocate the use of NMR rests on philosophical grounds: first, one
might argue that if we want to understand metabolism, we need to accurately quantify
all of the most abundant metabolites before delving into the analysis of femtomolar
trace components. Second, the more manipulation of the sample before analysis, the
greater the odds of introducing artifacts into the measurements. NMR is capable of
analyzing any biofluid or tissue sample directly, or, more commonly, after adding 10-
30% volume of D2O for field lock. Thus, at the very least, we would argue, NMR
data should be the first step in metabolomic analysis, with possible supplementation
by MS data for those metabolites below the NMR detection limit. Recently Crockford
et al. proposed a mathematical framework for integrating information obtained from
the MS and NMR data (Crockford et al., 2006), and this complimentary use of the two
techniques appears to be a very promising approach.
1.1.4 Multivariate Statistical Methods for Metabolomics
Having discussed the techniques used to acquire metabolomic data sets, we now turn
our attention to the statistical analysis of that data. While many methods are avail-
able, principal components analysis (PC analysis, or PCA) has been used succesfully
in a number of NMR-based metabolomic studies. PCA is a simple and elegant method
for reducing the dimensionality of multivariate data. Intuitively, the data for each
subject can be envisioned as a single point in a multidimensional vector space, where
the components of the vector are the measurements on that subject (e.g. concentra-
tions of various metabolites). When data have been collected for many subjects, if
there are differences in the metabolites between diseased and healthy individuals, then
the points will cluster into different groups in this multidimensional space. Princi-
pal components analysis represents a basis transformation in which new basis vectors
(”principal components”) are constructed so that the first one lies along the direction of
greatest variance in the data, the second is orthogonal to the first and lies in the direc-
tion of the most remaining variance, and so forth. Typically, the first several principal
components (PCs) describe on the order of 90% of the total variance in a metabolomic
data set. Provided that within a given data set the greatest source of variance is the
metabolic perturbation between experimental groups and controls, plotting the data
projected onto the new PCs very often allows 200-dimensional data to be visualized
7
in two or three dimensions, with clear separation of different groups. Moreover, the
largest components of the first few PC vectors, by definition, are the elements of the
data that explain the difference between groups. Thus PCA is simultaneously a tool
for visualization as well as identification of the biochemical differences between groups.
On the other hand, if plotting data projected onto the first few PCs does not show
appreciable clustering of different groups, this result indicates that the largest source
of variance within the data is not due to detectable biochemical differences between
the groups. (Here the word ”detectable” refers to the capabilities of the analytical
method(s) selected.) If intra-group variance exceeds the between-group variance (i.e.
the controls are more heterogeneous than any differences between the experimental
group and controls), one must consider whether a meaningful biochemical difference
exists, or if the null hypothesis may be correct. In the case that there is good reason
to reject the null hypothesis, some of the methods named in the following section may
be of use in focusing the analysis on whatever differences do exist between the control
and experimental groups.
A mathematical description of PCA may be found in Appendix C.
Other techniques
A detailed review of statistical methods for analysis of metabolomic data is beyond
the scope of this dissertation. For completeness, the following alternative procedures
deserve mention: partial least squares disriminant analysis (PLS-DA) (which is often
used in conjunction with orthogonal signal correction (OSC) (Gavaghan et al., 2002)),
and support vector machines (Joachims, 2002).
1.1.5 Metabolomics: Challenges
Generic Challenges
Though it is by no means unique to NMR-based metabolomics, the inability to quantify
all constituents of the metabolome represents a serious stumbling block for the field.
In general, measurement of the concentration of a small number of metabolite pools
provides enough data for speculation, but not enough to draw conclusions. A trivial
example serves to illustrate the point (Fig. 1.2).
In a pathway consisting of three metabolites, A, B, and C, if a metabolic per-
turbation increases B, decreases C, and leaves A unchanged, one can conclude that
decreased flux through the pathway catalyzed by protein 4 is the most straightforward
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1−→ A
2
⇀
↽
3
B
4−→ C 5−→
Group A B C Conclusion
Normal ↔ ↔ ↔ normal
Experiment 1 ↔ ↑ ↓ ↓ 4
Experiment 2 N.D. ↑ ↓ ↓ 4
Experiment 3 N.D. ↑ N.D. ↓ 4,5,3; ↑ 1,2
Experiment 4 N.D. N.D. ↓ ↓ 1,2,4; ↑ 3,5
Experiment 5 ↔ ↑ N.D. ↓ 4,5
Experiment 6 ↔ N.D. N.D. normal
Figure 1.2: Difficulties of interpreting incomplete metabolomic data in a simple path-
way with three metabolites A,B,C, and five fluxes catalyzed by proteins 1-5. N.D.,
indicates that the concentration was not determined in a given experiment. When all
concentration data are available, the correct conclusion is self-evident (experiment 1).
When data are missing, sometimes the correct interpretation can still be reached (ex-
periment 2), but in other cases, the data support only vague conclusions (experiments
3,4,5) or incorrect conclusions (experiment 6).
explanation. If the same situation occurs, but experimental limitations preclude the
measurement of A or B or C, it becomes more difficult to reach the correct conclusion.
If B and C (the metabolites upstream and downstream, respectively, of the altered
flux) can be measured (Experiment 2), then the correct conclusion is still obtained. On
the other hand, if this does not occur, then the data provide the basis for testable hy-
potheses, but they do not support definitive conclusions regarding the activities of the
five pathways. In the case where only one of the three metabolites could be detected
(not an altogether uncommon scenario in NMR- or MS-based metabolomics), conclu-
sions are either vague (Experiment 3,4) or incorrect (Experiment 6). The complexity
of the biochemical pathways (branching, cycles, etc.) in a living system compounds the
the problems illustrated by this trivial example. Thus a new approach involving the
measurement of flux through various pathways has been proposed (see §1.1.6 )
1.1.6 Beyond metabolomics: Fluxomics
As discussed in §1.1.5, interpreting data collected on a small fraction of the total number
of metabolites in a given pathway is a serious problem for metabolomics. Quantitative
analysis of all metabolites in a biological sample is a task of finite, but staggering, com-
plexity. It seems unlikely that high-throughput methods analogous to those available
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in the field of genomics will be forthcoming in the foreseeable future, in the sense that
it will not be possible to receive a complete and accurate analysis of all metabolites in a
sample within hours. The reason for this seemingly pessimistic view is as follows (Sum-
ner et al., 2003). By comparison, the human genome project, one of the most daunting
undertakings in history, involved the binary detection of only 4 structurally similar
molecules in the absence of dynamic range limitations. The analysis of all metabolites
in a sample is orders of magnitude more complex because, at a minimum, we would
expect to obtain data about carbohydrates, amino acids, lipids, fatty acids, nucleotides,
and sterols. The chemical properties of these molecules are so different that a single
instrument is unlikely to provide satisfactory results for all of them in a single sample.
Thus, for the present, we must either content ourselves with measuring a small fraction
of the metabolome, or think differently about the problem. Since an important goal of
metabolomic studies is the elucidation of mechanisms, as opposed to mere description
of biochemical changes in various disease states, a new approach is required.
The use of tracers to measure flux through various pathways has been proposed as an
alternative, complimentary approach to metabolomics . In addition to the arguments
presented above, which rested primarily on the grounds that incomplete metabolomic
data prevents definite conclusions about mechanisms for pathology, a separate case
can be made for the ”fluxomic” approach. Due to homeostatic mechanisms, organisms
will resist changes in concentration of regulated metabolites until physiologic reserve is
exhausted. Therefore, altered gene expression or enzyme function may precede mea-
surable changes in concentration of metabolites (especially if it is not possible to mea-
sure all metabolites reliably). On the other hand, a technique capable of measuring
metabolic flux may be much more sensitive in detecting a metabolic abnormality than
one which relies on concentration.
There are two key problems with the fluxomic approach: first, it is difficult to select
a single optimal tracer that will enable measurement of a useful number of fluxes. The
second problem is that tracers are expensive, and time-resolved data are required to
measure flux rates (although ratios of rates can be obtained from a single sample).
1.2 13C NMR as a Biological Tool
In order to fill the void in our understanding of biochemical mechanism left by concentration-
only metabolomic studies, we turn to 13C NMR-based measurements of metabolic flux.
Carbon atoms form the backbone of nearly all important biomolecules (see Appendix
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B). Naturally occurring samples contain a mixture of 98.9% 12C and 1.1% 13C, both of
which are stable nuclei that do not undergo any form of radioactive decay. Because 12C
contains an even number of nucleons, this nucleus has zero spin, and thus no magnetic
moment; therefore, it cannot be observed via NMR spectroscopy. However, the 1.1%
13C present in naturally occurring molecules has spin 1/2 and is observable via NMR.
Just as one may analyze complex mixtures of proton-containing biomolecules via 1H
NMRS, 13C NMRS can analyze complex mixtures of any molecules that contain 13C.
The key difference, however, is that the investigator is free to select 13C-enriched sub-
strates based on knowledge of stereochemistry in the pathway of interest. Due to the
high spectral resolution of 13C NMR spectroscopy, individual carbon atoms within a
molecule can be quantified independently. This data, when placed in the context of a
suitable biochemical model allows the investigator to reconstruct the metabolic history
of the carbons from the time they entered as the enriched tracer until they are ana-
lyzed in the metabolite of interest. It is possible to collect sequential in vivo 13C NMR
spectra, for example during the infusion of a tracer, and from this data to estimate the
rates of many biochemical pathways.
1.3 Astrocyte biology
We now turn our attention from the field of metabolomics to focus on astrocytes. As
we will see, these cells are potentially affected by chronic ethanol via a mechanism
involving acetate metabolism. Before focusing on this hypothesis, I will present some
background information on these fascinating and historically unappreciated cells.
Though long regarded as mere ”brain glue”, it has recently been appreciated that
astrocytes may play vital roles in many brain functions (Volterra and Meldolesi, 2005).
In addition to their traditional roles of providing scaffolds and metabolic support for
neurons, recent studies demonstrate that astrocytes may act as local networks, integrat-
ing neuronal inputs and modulating synaptic transmission. In this capacity astrocytes
may play critical roles in learning, memory, and higher-order cognitive functions.
1.3.1 Astrocyte Morphology and Ultrastructure
Limitations of classical staining techniques gave rise to the idea that multiple astrocytes
might extend overlapping processes to cover multiple neurons. However, more recent
techniques, such as the ability to microinject dye into a single astrocyte, reveal that
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GFAP Input Membrane Gap junction Glutamate NG2
expression resistance potential coupling staining
Type 1 High Low Very neg. Yes High Uptake Neg.
Type 2 Low High Less neg. No Low uptake Neg.
AMPA-Rs
Type 3 Low High Less neg. No Low uptake Pos.
AMPA-Rs
Table 1.1: Subtypes of astrocytes in the mouse hippocampus
astrocytes are far more organized, and that their processes show little overlap — each
astrocyte has its own domain that encompasses up to thousands of synapses (Bushong
et al., 2002). While a single astrocyte may envelop thousands of synapses, its interac-
tions with these synapses can be controlled independently via microdomains including
lamellipodia and filopodia (Volterra and Meldolesi, 2005). Thus the astrocyte itself
may integrate signals and selectively modulate various synapses — these are exactly
the characteristics one would expect of a communication hub. Moreover, astrocyte foot
processes appear to be plastic, extending, retracting and reorganizing on timescales of
minutes (Hirrlinger et al., 2004).
In addition to their role as integrators across networks of synapses, astrocytes serve
as bridges between cerebral vessels and neurons (Volterra and Meldolesi, 2005). In light
of their anatomical location and their ability to respond to neuronal activity, it has
been suggested that astrocytes may regulate CNS blood flow via release of potassium
in order to match perfusion to the metabolic demands of neuronal activity (Paulson
and Newman, 1987). Other relevant molecules that astrocytes may release to modulate
blood flow include epoxyeicosatrienoic acids (EETs), prostaglandins, and arachidonic
acid (Koehler et al., 2006).
Astrocyte subtypes
With the rise in interest in astrocytes, it has become clear that they are not a homoge-
neous cell type. Within the mouse hippocampus alone, at least three types of astrocytes
exist that differ in their expression of Glial fibrillary acidic protein (GFAP), proteogly-
can NG2, and other properties (see Table 1.3.1) (Volterra and Meldolesi, 2005). The
role and fate of NG2-positive cells remains unclear at this point — like astrocytes they
make intimate contacts with neurons throughout the grey and white matter, have stel-
late morphology, and extend processes to synapses. However they possess the ability to
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differentiate into oligodendrocytes, and may express different receptors and ion channels
(Nishiyama et al., 2005). These NG2 cells share with NG2-negative astrocytes the abil-
ity to be stimulated by neural input via glutamate, ATP, and possibly other molecules
(Butt et al., 2005). Yet NG2-positive cells are not the only histologic enigmas. On the
basis of slightly different criteria, six subtypes of astrocytes have been identified in rat
olfactory bulb (Bailey and Shipley, 1993). It seems very likely that within the category
of cells deemed ’astrocytes’, a great deal of morphologic and functional diversity has
been overlooked.
Astrocyte receptors
Among others, astrocytes express AMPA receptors, metabotropic glutamate receptors
(mGluRs), GABAB receptors, and muscarinic acetylcholine receptors, various adren-
ergic receptors, and receptors for adenosine, dopamine, serotonin, histamine, opioids,
substance P, and atrial natiuretic peptide (Porter and McCarthy, 1997).
1.3.2 Astrocyte Excitation and Ion Homestasis
Astrocytes possess intrinsic oscillating Ca2+ currents during development (Parri and
Crunelli, 2001), and afterwards . It has recently been appreciated that neuronal input
via astrocytic mGluRs, GABAB, and muscarinic ACh receptors can induce increases in
astrocytic Ca2+ , a form of astrocytic excitation (Newman, 2003). These Ca2+ increases
can propagate in waves to neighboring astrocytes, covering distances of hundreds of µm
(Cornell-Bell et al., 1990). The mechanisms for Ca2+ -wave propagation are (a) diffusion
of inositol trisphosphate (a second messenger for some mGluRs) through gap junctions
and (b) release of ATP that functions as an extracellular messenger (Newman, 2001). In
addition, neuronal input can modulate Ca2+ activity in astrocytes (Pasti et al., 1997).
The exact significance of these Ca2+ waves is incompletely known, but they appear to
play a role in physiologic modulation of synaptic activity by astrocytes (§1.3.3) and
also in epilepsy (Tian et al., 2005; Petroff et al., 2002; Khurgel and Ivy, 1996).
Astrocytes, with their large network of cells connected via gap junctions, are critical
buffers for extracellular K+ ions (Simard and Nedergaard, 2004). In addition to various
potassium channels, astrocytes have Na/K ATPases that pump sodium out of the
cell and potassium into the cell, thus maintaining Na+ gradients that are essential
for glutamate removal (Anderson and Swanson, 2000), while removing K+ from the
extracellular fluid to allow normal neuronal function.
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1.3.3 Astrocyte-Neuron Interactions
Metabolic interactions between Astrocytes and Neurons
Astrocytes provide metabolic support for glutamatergic and GABAergic neurotrans-
mission. (These are quantitatively the most important excitatory (Glu) and inhibitory
(GABA) systems in the brain.) Astrocytic support (Fig. 1.3) is crucial because they
possess two critical enzymes that neurons lack: glutamine synthase (GS) (Norenberg,
1979; Norenberg and Martinez-Hernandez, 1979), and pyruvate carboxylase (PC) (Yu
et al., 1983; Shank et al., 1985). In particular, glutamatergic transmission relies upon
the function of a glutamine-glutamate cycle in which neurons release glutamate, astro-
cytes remove it from the extracellular space and convert it to glutamine, and glutamine
is returned to neurons for the resynthesis of neurotransmitter glutamate (Sibson et al.,
1998). This cycle was first discovered by Benjamin and Quastel (Benjamin and Quas-
tel, 1972), and subsequently confirmed in numerous studies (Pellerin and Magistretti,
1994; Shen et al., 1999; Sibson et al., 1997), though some debate exists regarding sto-
ichiometry under various conditions, and which other substrates (if any) are shuttled
between astrocytes and neurons (Sibson et al., 1998; Zwingmann and Leibfritz, 2003;
Westergaard et al., 1995)
It is important to emphasize that neurons are completely dependent on astrocytes
for the de novo synthesis of glutamate because neurons lack the anapleurotic enzyme
pyruvate carboxylase (PC) (see Appendix B). Glutamate is a 5-carbon amino acid
that does not cross the blood brain barrier (Hawkins et al., 1995), but which can be
synthesized from glucose via the TCA cycle intermediate alpha-ketoglutarate (Hertz
et al., 2000). Yet for every molecule of glutamate produced, a five carbon skeleton is
lost from the TCA cycle. Without the activity of PC to replenish the carbon skeletons
in the TCA cycle by synthesizing oxaloacetate from pyruvate, it would impossible for
net synthesis of glutamate to occur.
In addition to the synthesis of neurotransmitters, astrocytes are the primary cells
responsible for synthesizing glutathione (GSH) within the CNS (Heales et al., 2004).
Glutathione is a tripeptide (γ-glutamylcysteinylglycine) that functions as an antiox-
idant because of its ability to donate electrons, and it is therefore a neuroprotective
compound (Hertz and Zielke, 2004); the lack of glutathione is itself neurotoxic (Jain
et al., 1991). Astrocytes provide neurons with the the GSH precursor L-cysteinylglycine
through a somewhat convoluted mechanism that involves astrocytic synthesis and re-
lease of GSH, and extracellular cleavage of GSH to L-cysteinylglycine (Dringen et al.,
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Figure 1.3: Astrocytes (left) possess the anapleurotic enzyme pyruvate carboxylase
(PC) which enables them to replenish TCA cycle intermediates that are lost during
net synthesis of glutamate. By contrast, neurons (right) express only pyruvate de-
hydrogenase, so that they can only form acetyl-CoA from pyruvate. Astrocytes also
express glutamine synthetase (GS) that enables them to convert glutamate (an exci-
tatory neurotransmitter) to glutamine that they release into the extracellular fluid for
neurons to scavenge. Neurons form glutamate from precursor glutamine supplied by
astrocytes, and they release it during neurotransmission. Astrocytes remove glutamate
from the extracellular space, preventing excitotoxicity. Key: large grey arrows indicate
ability to transport the specified molecule. Enzymes are italicized: ACoAS, acetyl-
CoA synthetase; GS glutamine synthetase; PAG phosphate-activated glutaminase; PC
pyruvate carboxylase; PDH pyruvate dehydrogenase. Metabolites: Ace, acetate; aKG,
alpha-ketoglutarate; Cit, citrate; Glc, glucose; Gln, glutamine; Glu, glutamate; OAA,
oxaloacetate; Pyr, pyruvate; Succ, succinate;
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1999).
Signalling Between Astrocytes and Neurons: Gliotransmitters
Astrocytes possess their own repertoire of ”gliotransmitters” that meet the criteria
specified by Volterra: (1) synthesis and/or storage in astrocytes, (2) regulated release
by physiological stimuli, (3) rapid (msec to sec) activation of responses in neighboring
cells, and (4) a role in physiological processes — see Table 1 in (Volterra and Meldolesi,
2005). Among the molecules that meet these criteria are: Glutamate, ATP, Adenosine,
D-Serine, various eicosanoids, TNF-α , and some peptide hormones.
Modulation of Synaptic Activity by Astrocytes
Astrocytes have at their disposal several means for modulating synaptic activity (New-
man, 2003). Following signals from neurons that induce Ca2+ waves, several mecha-
nisms allow astrocytes to modulate neuronal activity:
• Glutamate Release by Astrocytes:
Presynaptic neuronal activity can stimulate astrocytes to release glutamate, which
can have either a stimulatory or inhibitory effect on neurons. If glutamate acts
via postsynaptic mGluRs, the result is depression of both inhibitory and excita-
tory postsynaptic transmission. On the other hand, if glutamate acts via NMDA
or AMPA receptors on pre- or post-synaptic neurons, the result is an increase in
synaptic transmission. Thus in different contexts, glutamate release by astrocytes
can have either a positive or negative neuromodulatory effect.
• ATP Release by Astrocytes
Muller cells (specialized retinal astrocytes) modulate synaptic activity via release
of ATP. Like glutamate, ATP can have either an excitatory or inhibitory effect
on neurotransmission. ATP can interact with P2X neuronal receptors to mediate
a stimulatory effect. On the other hand, ATP can be cleaved to adenosine in the
extracellular space, and adenosine can produce an inhibitory effect via adenosine
A1 receptors through an increase in K+ conductance.
• Cofactor release
Astrocytes are the sole source of D-serine, a necessary cofactor for NMDA receptor
activation. NMDA receptor activation requires occupancy at both the glutamate
site as well as a so-called ”glycine” site for which D-serine appears to be the
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endogenous ligand. Thus release of this cofactor by astrocytes provides a plausible
mechanism for modulating synaptic activity.
• Glutamate Transport
As discussed above (§1.3.3), a glutamine-glutamate cycle operates between neu-
rons and astrocytes. Moreover, astrocytes are entirely responsible for maintaining
the low (3-4 M) extracellular concentration of glutamate through a process of co-
transport with sodium and protons, followed by rapid conversion to glutamine
(Danbolt, 2001). Thus, modulation of glutamate uptake provides a potential
mechanism for astrocytes to influence synaptic transmission. On the other hand,
as we will see in (§1.3.4), failure of astrocytes to supply precursor glutamine to
neurons inhibits glutamate-dependent processes.
• Extracellular Ions
Astrocytes are also responsible for extracellular ionic homeostasis in the brain
(Simard and Nedergaard, 2004). If they allow the extracellular K+ levels to rise,
the effect will be to depolarize neurons and increase synaptic transmission. (As
discussed in §1.3.1, increasing extracellular potassium may be a form of commu-
nication between astrocytes and vascular smooth muscle.) On the other hand, if
astrocytes allow H+ levels to rise, the effect will be to block presynaptic Ca2+
channels and NMDA-Rs, thus decreasing synaptic transmission.
1.3.4 Roles of Astrocytes in Behavior and Integrated Physi-
ology of the Organism
Clock genes and EEAT1/GLAST
A set of so-called ”clock” genes named period 1,2,3 (Per1, Per2, Per3) plays a role in
controlling diurnal rhythms. A ”master clock” is located in the suprachiasmatic nuclei
of the brain, and not surprisingly, the regulation is quite complex (Albrecht and Eichele,
2003). Nevertheless, knockout mice deficient in Per2 showed decreased expression of the
glutamate transporter EEAT1 (GLAST) in astrocytes, leading to a hyperglutamatergic
state in the brain (Spanagel et al., 2005; Yuferov et al., 2005). This finding suggests a
connection between astrocytic glutamate transport and control of circadian rhythms.
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Glutamatergic activity and learning
Due to their role in providing metabolic support for glutamatergic neurons (§1.3.3),
normal astrocyte function is required for certain types of learning. Disruption of the
supply of precursor glutamine through inhibition of either the astrocytic TCA cycle or
glutamine synthase quickly abolishes glutamate release by neurons (Hertz and Zielke,
2004). Inhibition of of the astrocytic TCA cycle by fluoroacetate in day-old chicks was
shown to inhibit glutamate-dependent aversive learning, but injection of glutamate
restored normal learning even in the presence of fluoroacetate (Hertz et al., 1996).
Thus, to the extent that certain types of learning are dependent upon glutamatergic
activity, astrocytic support of glutamatergic neurons is indispensable.
Glucose Homeostasis
As discussed in (§1.3.3) astrocytes may supply neurons with lactate derived from glu-
cose. A recent study found that intraventricular injections of either glucose or L-lactate
increased blood insulin and decreased blood glucose due to decreased hepatic glucose
production (Lam et al., 2005). Moreover, neither injection of D-lactate (which can-
not be converted to pyruvate within neurons), nor co-injection of L-lactate with the
lactate dehydrogenase inhibitor, oxamate, caused similar changes, supporting the idea
that neuronal metabolism of lactate to pyruvate is an essential step in this regulatory
mechanism. Since inappropriately high production of glucose by the liver is at least
partially responsible for diabetic hyperglycemia (Vaag et al., 1995; Taylor, 1999), it
is possible that deficient astrocytic supply of L-lactate to neurons could be partially
responsible for failure of homeostatic regulation of blood glucose in type II diabetes.
Oxytocin release and Lactation
During conditions that are associated with oxytocin and vasopressin release (childbirth,
lactation, water deprivation), astrocytic processes, which normally provide dense cover-
age of neuronal elements, retract (Hirrlinger et al., 2004; Oliet et al., 2004). In nursing
rats, new axosomatic synapses appear after the astrocytic processes recede. These new
synapses may play a role in synchronizing output from these neurons, helping them to
secrete large amounts of hormone (Hatton, 1997). These changes reverse themselves
after removal of the stimulus (i.e. weaning pups or correcting fluid balance) (Hatton,
1997). These findings suggest the intriguing possibility that one function of astrocytes
is to inhibit the formation of inappropriate neural connections, and that the removal
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of foot processes enables the formation of new connections in adult brain. Further, it
suggests that reinstatement of normal astrocytic function may abolish the synchronous
activity induced by the new synapses. Finally, it is appealing to speculate that cells that
are involved in the hormonal regulation of fluid balance might also play a role in the
perception of thirst, thus providing another possible link between astrocyte dysfunction
and alcoholism.
1.4 Alcohol abuse and alcoholism
Ethanol not only damages multiple organ systems, causing significant morbidity and
mortality, but the social and economic consequences of its abuse are staggering. While
it is impossible to quantify the human cost, the estimated cost of alcohol abuse and alco-
holism is more than $100 billion annually in the US (Holland and Mushinski, 1999), and
is similarly staggering elsewhere (Fenoglio et al., 2003; Devlin et al., 1997). Ethanol
remains the third leading external cause of death in the United States, behind to-
bacco, and poor diet and inactivity (Mokdad et al., 2004; McGinnis and Foege, 1993).
Withdrawal from ethanol can be deadly; those who survive carry a burden of neural
sensitization that predisposes to craving and relapse (De Witte et al., 2003; Becker,
1996).
1.5 Ethanol Metabolism and Biodistribution
In humans, ethanol is typically consumed as a beverage. When ingested this way,
it quickly reaches the stomach (Fig. 1.4). If the stomach is empty, the majority
of the dose will be absorbed from the duodenum and jejunum into the blood of the
hepatic portal system. On the other hand, solid food, if present in the stomach, will
delay emptying of gastric contents, and up to 70% of the dose can be absorbed via the
stomach itself, albeit at a slower rate (Eckardt et al., 1998). When transit time through
the stomach is delayed by the presence of food, first-pass metabolism by gastric Alcohol
Dehydrogenase (ADH, see below) occurs, though all but the smallest doses of ethanol
will saturate the gastric ADH system. Thus in nearly all cases, ethanol will travel
via the portal vein to the liver, where the vast majority of ethanol oxidation occurs.
When ethanol is present in concentrations that saturate the liver’s metabolic capacity,
it will enter the systemic circulation, and distribute in total body water (Eckardt et al.,
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Figure 1.4: Ethanol ingestion, absorption, and biodistribution. Ethanol is absorbed
from the the gastrointestinal tract into the portal vein (and to a lesser extent into the
systemic circulation). First-pass metabolism of ethanol to acetaldehyde and acetate
occurs primarily in the liver, and all three compounds are released into the circulation.
Blood levels of ethanol range from 12mM for a 0.5g/kg dose to hundreds of mM in
tolerant alcohol abusers; blood acetaldehyde levels are typically 0-2 µM, and blood
acetate is typically 1-2mM. The vast majority of a dose of ethanol is eliminated via
hepatic oxidation to acetate; a small portion of ethanol is excreted renally, exhaled, and
excreted in the sweat. Ninety percent of the acetate produced via ethanol oxidation
is released into the blood where it travels to many organs and is used as a source of
energy. A key hypothesis in this dissertation is that the brain adapts to this unusual
energy source, and that resulting dependence on acetate as a substrate for cerebral
metabolism is a component of dependence to ethanol.
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Figure 1.5: Significant routes for hepatic ethanol oxidation. The primary pathway
for ethanol metabolism in naive animals involves the cytoplasmic Alcohol Dehydroge-
nase (ADH) and mitochondrial Aldehyde Dehydrogenase (ALDH). In ethanol-tolerant
individuals, the inducible Microsomal Ethanol Oxidizing System (MEOS) can also con-
tribute significantly.
1998). The ’classical’ ethanol-oxidizing system involves two enzymes, cytosolic Alcohol
Dehydrogenase (ADH) and intramitochondrial Aldehyde Dehydrogenase (ALDH).
The equilibrium of the ADH reaction at pH 7.3 favors the formation of ethanol,
but the ALDH reaction is faster and irreversible. Thus, provided that NAD+ may
be regenerated in the mitochondria, the net reaction favors the oxidation of ethanol
(Eckardt et al., 1998). Comparatively recent reports have shown the importance of
the Microsomal Ethanol Oxidizing System (MEOS) which is comprised of various cy-
tochrome P450 isoforms and distinguished from the ADH system on the basis that the
MEOS is (i) oxygen and NADPH-dependent, rather than NAD+-dependent, and (ii)
inducible (Lieber and DeCarli, 1970). In addition, a catalase system has been suggested
to metabolize ethanol, although the quantitative significance of this pathway in vivo
appears to be minimal (Lieber, 1999).
At high hepatic ethanol concentrations, a small amount of ethanol is eliminated
via conjugation with activated UDP glucuronic acid (uridine-5’-diphospho- -glucuronic
acid) in the presence of UDP glucuronyl transferase, forming ethyl glucuronide (EtG).
Though it is certainly not a quantitatively important route for ethanol elimination
(<0.5-1.5% of a dose of ethanol is excreted in urine as EtG (Wurst et al., 2002)), the
slow release of EtG from the liver and subsequent storage in the hair, or elimination
in the urine, make EtG a promising forensic marker of recent ethanol abuse (Droenner
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et al., 2002)(Wurst et al., 2003). For completeness, it is worth mentioning that small
amounts (<5% of a given dose) of ethanol may be eliminated by the kidneys, skin, and
lungs (Norberg et al., 2003). Also, the brain has been suggested to possess some ability
to oxidize ethanol, but reports have been inconsistent and at most the brain appears
to have 0.1-1% of the ethanol-oxidizing capacity of the liver (Eckardt et al., 1998).
1.6 The Effect of Ethanol on Energy Metabolism
Much of the impact of ethanol metabolism on the liver can be understood in terms
of the change in Oxidation-Reduction (redox) state. Oxidation of ethanol results in
excess production of NADH (see §1.5), which drives the equilibrium of reactions that
require reduced cofactors away from oxidation of other substrates. In particular, the
increased NADH/NAD ratio drives a shift from oxaloacetate to malate in the TCA
cycle, and may therefore slow the TCA cycle (Mayes, 2000). Thus products of ethanol
metabolism (acetate, NADH, NADP) slow the oxidation of fatty acids (see Fig. 1.6).
The result is increased esterification of fatty acids to form triacylglycerol, which is likely
the basis for alcoholic fatty liver disease (Mayes, 2000). As we will see in chapter 3,
in vivo ethanol metabolism impairs gluconeogenesis (though the situation can be a bit
more complex in isolated liver). The simultaneous inhibition of glucose production and
increased output of acetate, which can supply 2-carbon units for oxidative metabolism
in the TCA cycle (§B.1), suggests that many tissues may adapt to increase metabolism
of this unusual energy source.
In vertebrates, there is only a single enzyme through which acetate can partic-
ipate in metabolism: acetate can enter the TCA cycle after being converted into
Acetyl-CoA via Acetyl-CoA Synthetase (ACoAS) (EC 6.2.1.1) (see §B.1); thus, ac-
etate lies only two reactions away from this hub of metabolism (Kanehisa et al., 2006).
In addition, it is worth noting that a pair of acetyl-CoA molecules can condense to
form acetoacetyl-CoA via Acetyl-CoA Acetyltransferase (ACoAT) (EC 2.3.1.9). From
acetoacetyl-CoA, HMG-CoA Synthase (EC 2.3.3.10) catalyzes the formation of 3-
Hydroxy-3-methylglutaryl-CoA (HMG-CoA) that represents a crossroads between the
formation of ketone bodies and the synthesis of sterols.
In addition to the liver, which actually releases more than 90% of the acetate it
produces during ethanol metabolism (Jucker et al., 1998), many tissues have the ca-
pacity to metabolize acetate. As we will see, acetate is a substrate for astrocytes in
the brain (Waniewski and Martin, 1998; Zwingmann and Leibfritz, 2003). Acetyl-CoA
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Figure 1.6: Ethanol-Induced Lipogenesis
synthetase is a phylogenetically ancient enzyme that is well conserved in eubacteria,
archeaebacteria, and eukaryotes (Karan et al., 2001). It is found in mitochondria, and
thus it stands to reason that for cells that possess mitochondria (i.e. all cells except red
blood cells), the major impediment to using acetate as a substrate may be the ability to
transport it across the plasma membrane (Waniewski and Martin, 1998). 13C and 14C
studies have shown that rat skeletal (Bertocci and Lujan, 1999), and cardiac muscle
(Tran-Dinh et al., 1998) utilize acetate, as does hog vascular smooth muscle (Allen and
Hardin, 1998). Similar studies have shown that rabbit kidney tubule (Chauvin et al.,
1997), and rat adipocytes can metabolize acetate (Borges-Silva et al., 2005). (Although
rabbits apparently have relatively high blood acetate concentrations, as compared to
humans or rats (Chauvin et al., 1997).)
1.7 EtOH and brain
Though most people are familiar with the effects of various doses of ethanol on behavior,
the neurochemical basis for these effects remains incompletely understood, in large part
because ethanol interacts with a number of neurotransmitter systems. Rather than
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explore all of these, the following section will review the effect of ethanol on glutamate
and GABA systems, since these are the ones we will probe with the 13C experiments
described in Chapter 4.
1.7.1 Ethanol Dependence and Withdrawal
Chronic ethanol consumption results in dependence that is characterized by tolerance
and a hyperexcitable withdrawal syndrome that includes anxiety, tremors, and occa-
sionally seizures. This hyperexcitability is attributed to the brains inability to quickly
reverse the neuroadaptations that confer tolerance to ethanol (De Witte et al., 2003):
increased sensitivity of glutamate-NMDA receptors (Rudolph et al., 1997; Chandler
et al., 1993) and decreased sensitivity of GABAA receptors (Devaud et al., 1997).
When ethanol is present, these adaptations allow surprisingly normal brain function,
even at ethanol concentrations that would induce coma in ethanol-naive individuals.
However, cessation of ethanol consumption results in a positive feedback cycle of hy-
perexcitability and increased glutamate release (Tsai and Coyle, 1998; Dahchour et al.,
1998). Withdrawal from ethanol represents a neurotoxic event (Tsai and Coyle, 1998),
and repeated episodes of withdrawal have a cumulative detrimental effect (Ballenger
and Post, 1978). While the basis for withdrawal-related neurotoxicity is only partially
understood, increased extracellular glutamate plays an important role (De Witte et al.,
2003; Tsai et al., 1995). Glutamate, the principal excitatory neurotransmitter in the
brain, is neurotoxic if released in large quantities, or when not promptly removed from
the extracellular space by astrocytes (Danbolt, 2001). Just as altered receptor sensi-
tivity allows pharmacologic tolerance to ethanol (yet represents pathology because it
contributes to hyperexcitability during withdrawal), enhanced acetate metabolism in
astrocytes may represent metabolic tolerance that becomes pathologic when acetate is
removed, decreasing the capacity for astrocytic uptake of glutamate. Traditionally, the
focus in alcohol research has been on neuronal pathology following ethanol exposure,
with astrocytes neglected completely or regarded as passive bystanders. Recent evi-
dence, however, suggests that the functional significance of astrocytes may have been
overlooked.
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1.7.2 Altered astrocyte function: A Potential Biochemical Ba-
sis for Dependence and Craving
Spanagel et al. showed that increased voluntary alcohol consumption in a strain of
mice possessing a particular mutation is due to decreased expression of the glutamate
transporter EAAT1 (excitatory amino acid transporter 1; also known as GLAST) on as-
trocytes, leading to increased extracellular glutamate in the ventral striatum (Spanagel
et al., 2005). This finding supports the concept that craving and relapse may re-
sult from an attempt to decrease anxiety and other symptoms of hyperexcitability by
self-medication with ethanol (De Witte, 2004). Moreover, it demonstrates that astro-
cytic pathology can itself produce a hyperglutmatergic state with direct relevance to
ethanol consumption. The predominant mechanism for cellular uptake of glutamate
in the brain is transport into astrocytes (Anderson and Swanson, 2000). Astrocytic
glutamate transporters rely upon sodium and potassium concentration gradients; these
gradients require energy. During ischemia, reversal of the glutamate transporter on
astrocytes accounts for approximately half of glutamate released into the extracellular
space (Phillis et al., 2000), but transporter reversal precedes complete collapse of ionic
gradients, suggesting that less severe energy compromise may still produce physiologi-
cally significant decreases in glutamate uptake (Jabaudon et al., 2000). It is therefore
logical to assume that if adaptation of astrocytes to utilize acetate produces lasting
deficits in glutamate uptake, the resulting increased extracellular glutamate might con-
tribute to anxiety, craving, and other processes that complicate recovery from ethanol
addiction.
If cessation of chronic alcohol ingestion (and therefore acetate production) con-
tributes to withdrawal due to metabolic failure in astrocytes and reduced glutamate
uptake, then administration of acetate during withdrawal should reduce withdrawal
severity. In the only publication we could find on this topic, Derr et al. (Derr et al.,
1981) found that intragastric (i.g.) injections of sodium acetate significantly reduce the
incidence of whole body tremors in rats following Majchrowiczs 4 day ethanol exposure
paradigm (Majchrowicz, 1975). Though published in a somewhat obscure journal and
not replicated during the past 24 years, this result is consistent with the hypothesis that
acetate administration during withdrawal supplies the brain with a critical substrate
for astrocytic metabolism and thereby averts tremors during withdrawal. Although
it supports our hypothesis of a metabolic contribution to ethanol/acetate dependence
and withdrawal, this result does not provide definitive proof: evidence is lacking that
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(i) metabolic adaptation results from chronic exposure to ethanol and acetate, and (ii)
cessation of ethanol intake (and therefore acetate production) causes metabolic pathol-
ogy that precedes and contributes to hyperexcitability. The experiments described in
this dissertation will address both of these issues. Whereas complete metabolic fail-
ure of astrocytes can produce toxic overabundance of extracellular glutamate, other
metabolic pathology in astrocytes can decrease glutamatergic neurotransmission, and
this phenomenon may also be significant in alcoholism. Neurons rely on astrocytes for
metabolic support, including supply of precursors for synthesis of glutamate. Inhibi-
tion of the astrocytic TCA cycle or glutamine synthetase impairs release of transmitter
glutamate (Hertz and Zielke, 2004), leading to cognitive deficits. Inhibition of the
astrocytic TCA cycle by fluoroacetate in day-old chicks inhibits glutamate-dependent
aversive learning, but injection of glutamate overcomes this effect (Hertz et al., 1996).
If astrocytes fail to support neuronal synthesis of glutamate required for aversive learn-
ing, this could contribute to perseverative behavior observed after withdrawal (Obernier
et al., 2002b) that interferes with recovery. In addition, recent evidence implicates as-
trocytes as active participants in synaptic events, capable of releasing glutamate in a
Ca2+-dependent fashion (Newman, 2003). Thus, astrocytes may be involved with more
subtle forms of cognitive function, and disruption of these could also be a significant
obstacle to recovery from ethanol addiction.
1.7.3 Ethanol & Cerebral Metabolism: Availability of Acetate
During Intoxication
Ethanol is oxidized to acetate in the liver, and more than 90% of this acetate is released
into the blood (Jucker et al., 1998). In the absence of ethanol, a small amount of acetate
is produced by bacterial flora, leading to a blood acetate concentration of 0.2-0.3mM
(Waniewski and Martin, 1998). In humans given a single dose of ethanol (0.5g/kg i.v.),
blood acetate rises 3-fold to approximately 1mM (Orrego et al., 1988). In rats, similar
increases were observed after a single intraperitoneal dose of ethanol (Carmichael et al.,
1991) (also, see Fig. 3.2). Elimination of intoxicating doses of ethanol occurs at a
constant rate (zero-order kinetics (Norberg et al., 2003)), which implies a constant rate
of acetate production. Following a single dose of ethanol, blood acetate remains at a
constant level until ethanol metabolism is nearly complete (and no longer zero order)
(Orrego et al., 1988). Thus, it is reasonable to suppose that an individual on a binge
may have peaks and valleys in blood ethanol concentration, but that blood acetate
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will remain at a relatively constant, elevated level until intake ceases and virtually
all ethanol is eliminated. During chronic ethanol exposure, metabolic tolerance to
ethanol in the liver ensues, increasing the rate of ethanol oxidation in both humans and
animals (Lieber and DeCarli, 1970). Since ethanol is oxidized to acetate at a faster rate,
alcoholics reach a higher blood acetate plateau (mean 1.48mM, max 1.90mM) during
intoxication than do occasional drinkers and controls (Korri et al., 1985), demonstrating
that there is a more abundant supply of acetate in the blood during prolonged ethanol
consumption.
1.7.4 Ethanol & Cerebral Metabolism: Cerebral Utilization
of Acetate
Early studies using [14C] acetate demonstrated that carbons from acetate were prefer-
entially incorporated into cerebral glutamine rather than glutamate, while the reverse
occurred when [14C] glucose was provided as the tracer molecule (O’Neal and Koeppe,
1966). These observations gave rise to the hypothesis that cerebral metabolism consists
of two compartments: one that preferentially metabolizes acetate and contains a small
glutamate pool that is rapidly converted to glutamine, and a second compartment that
utilizes glucose and contains a large glutamate pool (Van den Berg et al., 1969). Since
astrocytes express glutamine synthase (Norenberg and Martinez-Hernandez, 1979), it
was supposed that they represent the small glutamate pool, and that cerebral acetate
metabolism takes place mainly within astrocytes. This view is now widely accepted
((Zwingmann and Leibfritz, 2003) and references therein), and it has been shown that
the selectivity of acetate in labeling the astrocytic compartment is due to avid uptake
by a specific acetate carrier on astrocytes (Waniewski and Martin, 1998). Not only is
exogenous acetate a substrate for brain metabolism, but Roach et al. also showed that
[14C] ethanol given intraperitoneally labeled brain Gln, Glu, and GABA (Roach and
Resse, 1972). This result is presumably due to cerebral metabolism of [14C] acetate,
though the 13C NMR studies in this proposal will provide more definitive data. Further,
activity of ACoAS (the enzyme that converts acetate to acetyl-CoA) increases 36% in
homogenates of rat cortex following chronic ethanol treatment (Kiselevski et al., 2003).
Taken together, these observations support the hypothesis that during chronic ethanol
intoxication, astrocytes adapt their metabolism to utilize the unusually abundant sup-
ply of blood acetate.
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1.8 Outline of Dissertation
1.8.1 Metabolomic Studies
We began with an NMR-based metabolomic study of the effect of ethanol on liver,
blood, and brain biomolecules. Along the way we investigated several unknown peaks
in the NMR spectra, and Chapter 2 details our assignment of one of the unknown
signals to ethyl glucuronide. In Chapter 3 we present all of the findings from the
metabolomic analysis, including (i) ethanol inhibits gluconeogenesis, (ii) high doses of
ethanol produce ethyl glucuronide in the liver within 3 hours, (iii) the anti-oxidant
BHT inhibits the formation of ethyl glucuronide.
1.8.2 13C NMR Analysis of Brain Metabolism
In order to address the hypotheses presented above regarding cerebral metabolism of
ethanol-derived acetate, we used 13C tracers and 13C NMR spectroscopy of tissue ex-
tracts. To our knowledge, this is the first study of brain metabolism of ethanol-derived
aceate using 13C methods; the results are presented in Chapter 4. The 13C fractional
enrichment data provide the strongest support to date for the concept that ethanol-
derived acetate is metabolized in brain. Contrary to our expectations, chronic ethanol
exposure did not increase the net cerebral utilization of acetate, probably because trans-
port of acetate into astrocytes did not increase substantially. However, chronic ethanol
caused significant alterations in labeling of the neurotransmitter GABA, which may
reflect neuroadaptation in dependent animals.
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Chapter 2
Proton NMR Spectroscopic
Determination of Ethanol-Induced
Formation of Ethyl Glucuronide in
Liver
The following chapter is the first report describing detection of ethyl glucuronide in
liver by proton NMR spectroscopy. It has been submitted to Analytical Biochemistry.
2.1 Abstract
Ethyl glucuronide (ethyl-β-D-6-glucosiduronic acid, EtG), a unique metabolite of ethanol,
has received much recent attention as a sensitive and specific biological marker of
ethanol consumption. Formed in the liver via conjugation of ethanol with activated
glucuronate, EtG remains detectable in serum, plasma, and hair for days after ethanol
abuse. Thus far, GC-MS and ELISA assays have been developed to detect trace quan-
tities of EtG for forensic purposes, but reports of the NMR properties of EtG have
been scarce. Herein we present the first report of EtG determination using proton
NMR spectroscopy. We collected 700MHz proton spectra of liver extracts from rats
treated with a 4-day binge ethanol protocol (average ethanol dose: 8.6 g/kg/day). An
unexpected signal (triplet, 1.24 ppm) appeared in ethanol-treated liver extracts but
not in control samples; based on chemical shift and multiplicity, we suspected EtG. We
observed quantitative hydrolysis of the unknown species to ethanol while incubating
our samples with β-glucuronidase, confirming that the methyl protons of EtG were
responsible for the triplet at 1.24ppm. This study demonstrates that proton NMR
spectroscopy is capable of detecting EtG, and that future NMR-based metabolomic
studies may encounter this metabolite of ethanol.
2.2 Introduction
Ethyl glucuronide (ethyl-β-D-6-glucosiduronic acid, EtG) is a minor direct metabolite
of ethanol that has received much recent attention as a sensitive and specific bio-
logical marker of ethanol consumption. Due to interest in developing methods capa-
ble of detecting minute quantities of this compound for forensic applications (Wurst
et al., 1999; Droenner et al., 2002; Skipper et al., 2004), efforts have focused on gas
chromatography-mass spectrometry (GC-MS) (Schmitt et al., 1995; Weinmann et al.,
2004; Wurst et al., 2004), and even enzyme linked immunosorbant assay (ELISA) tech-
niques (Zimmer et al., 2002), but the nuclear magnetic resonance (NMR) properties of
EtG have not been reported to our knowledge. In the emerging field of metabolomics,
NMR spectroscopy is a prominent tool for the analysis of compounds found in biofluids
and tissue extracts (Reo, 2002; Griffin, 2003; Viant et al., 2003) because it is capa-
ble of detecting many classes of molecules in the same sample without pre-selection
of analytes (Imbenotte et al., 2003). Moreover, the sensitivity of NMR has increased
dramatically in recent years due to technical advances such as cold probes that increase
the signal to noise ratio, small volume sample tubes that allow the detection of smaller
amounts of material, and improved digital electronics that increase the effective dy-
namic range of the technique. These advances extend the detection limit for NMR and
thus increase the number of compounds which may be identified during experiments
and screening tests. As the number of detected compounds grows, it will be of great
use to have access to publications that give NMR spectral properties for molecules that
have not yet received great attention. Therefore, we present what is to our knowledge
the first published report describing the detection of ethyl glucuronide by proton NMR
spectroscopy. We hope that the presentation of this information will facilitate the cor-
rect interpretation of NMR data from future clinical and animal metabolomic studies
in which ethanol intake is a possibility.
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2.3 Materials and Methods
2.3.1 Animals
Adult male Sprague Dawley rats (275-325g) were treated with a modified 4 day binge
ethanol protocol as previously described (Obernier et al., 2002a). A 15% (w/v) ethanol
Reitz High Fat diet was used with an appropriate isocaloric control. Rats were given an
initial dose (5g/kg, 25%w/v, in a vehicle of nutritionally complete diet) with subsequent
doses determined using a six-point behavior scale (Majchrowicz, 1975). Control animals
received a diet equal to the average of all ethanol treated animals. All animals had free
access to water throughout experiment. This protocol produces physical dependence
to ethanol (Majchrowicz, 1975) and induces neuropathology modeling that found in
human alcoholics (Obernier et al., 2002a). Blood ethanol concentration (BEC) was
measured using electrochemical detection of an enzymatic reaction with an Analox
Instruments model GM-7 analyzer (Analox Instruments, MA). Ethanol groups had
mean blood levels around 300 mg/dl (range 250-375 mg/dl). Within one hour after
the last treatment, all animals were sacrificed, and liver samples were collected and
stored at -80 C until further analysis. All protocols in this study were approved by the
Institutional Animal Care and Use Committee and were in accordance with National
Institute of Health regulation for the care and use of animals in research.
2.3.2 Tissue Extraction and Sample Preparation
Liver tissues were removed from the -80 C freezer and placed in liquid nitrogen. Tis-
sues were then pulverized with a stainless steel mortar and pestle, and extracted with
perchloric acid (Fan et al., 1986). The extracts were lyophilized, dissolved in D2O
containing TSP and formate (as frequency and concentration references, respectively),
and adjusted to pH 7.0 (pD 6.6) with DCl or NaOD prior to NMR analysis.
2.3.3 Enzymatic hydrolysis
To confirm the presence of a glucuronide, we performed an enzymatic hydrolysis by
adding 2500IU β-glucuronidase (E.C. 3.2.1.31) (Scarfe et al., 2002) from Helix pomatia
crude extract (MP Biomedicals, Inc., Irvine, California). We acquired ”pre-incubation”
proton spectra after adjusting the pH of the liver extracts to 5.0 (pD 4.6) for optimal
activity of the H. pomatia enzyme using 7M DCl. After acquiring a pre-incubation spec-
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Figure 2.1: Typical 700MHz 1H spectrum of liver extract from an animal treated with
ethanol (a) shows a triplet at 1.24ppm which was later confirmed to be due to ethyl
glucuronide. This signal is not due to ethanol, which resonates at 1.19ppm (see Fig.
2.2c). The triplet was absent from spectra of liver extracts from animals that were
not given ethanol (b). Abbreviations: alanine, Ala; ethanol, EtOH; ethyl glucuronide,
EtG; β-hydroxybutyrate, 3HB; lactate, Lac.
trum, enzyme was added to the liver extract samples, and the samples were incubated
overnight in a 37◦C water bath. As a positive control, Methyl Glucuronide (Sigma, St.
Louis, Missouri) was incubated with β-glucuronidase under the same conditions.
2.3.4 NMR spectroscopy
Initial studies were conducted on a Varian Inova 700MHz spectrometer. Proton spectra
were acquired in fully relaxed mode (duty cycle = 45s), at 25◦C, with 1s presatura-
tion of water protons immediately prior to a 90◦ excitation pulse. Other parameters
were: 16 transients, spectral width 8600Hz, 64k data points. Hydrolysis of EtG by
β-glucuronidase was monitored on a Varian Inova 400MHz spectrometer. Spectra col-
lected before and after overnight incubation were acquired at 25◦C with 45s duty cycle,
1.5s presaturation of water protons, 90◦ excitation pulse, 8 transients, 4000Hz spec-
tra width, and 16k data points. Sequential spectra acquired during incubation with
β-glucuronidase were acquired at 37◦C, with identical parameters except that 32 tran-
sients were acquired for each spectrum.
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Figure 2.2: Identification of ethyl glucuronide in proton NMR spectra of liver extracts.
400MHz 1H spectra acquired before (a) and after (b) overnight incubation with β-
glucuronidase show decreased intensity of the EtG triplet, and formation of ethanol.
Spectrum (c) from the same sample after addition of pure ethanol, which resonates
at 1.19ppm, confirms that the triplet at 1.24ppm is not ethanol, and that ethanol is
the product of the reaction. Panel (d) shows the hydrolysis of EtG to glucuronate +
ethanol catalyzed by β-glucuronidase.
2.3.5 EtG Standard
A sample of EtG (Aurora Analytics, Baltimore, MD) was obtained in order to validate
spectral assignments.
2.4 Results and Discussion
Analysis of 700MHz proton spectra of liver extracts revealed an unexpected triplet at
1.2380±0.006ppm (J = 7.11±0.05Hz) (data reported as mean±standard deviation of
11 samples). This triplet was present in all spectra of liver extracts from animals that
received ethanol (n=11, see Fig. 2.1a for a representative spectrum), and absent from
control samples (n=11, see Fig. 2.1b). The multiplicity of this signal suggested the
presence of an ethyl group, but the chemical shift was inconsistent with ethanol, which
was confirmed by adding a small amount of ethanol to the sample, reacquiring data at
400MHz, and observing a distinct triplet at 1.19ppm (Fig. 2.2). Based on the presence
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Figure 2.3: Spectra acquired before (a) and after (b) overnight incubation of an EtG-
containing liver extract without addition of β-glucuronidase show no evidence of either
decreased EtG intensity or formation of ethanol, demonstrating that the reaction in
Fig. 2.2a,b is due to enzymatic activity rather than non-specific degradation. Spectra
of an extract from control liver that contained no EtG acquired before (c) and after
(d) overnight incubation with β-glucuronidase show no formation of ethanol due to
incubation, demonstrating a specific requirement for the species that gives rise to the
triplet at 1.24ppm as a substrate for the production of ethanol.
of an ethyl group associated with exposure to large doses of ethanol, we suspected
that the unassigned triplet was due to ethyl glucuronide (C8H14O7, see Fig. 2.2d for
structure). Comparison of spectra from a liver sample acquired before (Fig. 2.2a) and
after (Fig. 2.2b) overnight incubation with β-glucuronidase reveals hydrolysis of EtG
to ethanol + glucuronate in a liver extract from an ethanol-treated animal. Incubation
with β-glucuronidase resulted in decreased intensity of the triplet at 1.24ppm (EtG),
with a corresponding increase in the intensity of the triplet at 1.19ppm (ethanol, Fig.
2.2b). The identity of the triplet at 1.19ppm was confirmed by observing an increased
intensity in this triplet in a spectrum acquired after adding ethanol directly to the
samples (Fig. 2.2c).
We performed several controls to validate our procedures. In order to rule out
the possibility that incubation at 37◦C and pH 5 caused non-specific formation of
ethanol, we incubated one extract from ethanol-treated liver without addition of β-
glucuronidase, and as expected no ethanol formation or EtG hydrolysis were observed
(Fig. 2.3a,b). This finding shows that the reaction observed in Fig. 2.2a,b was cat-
alyzed by β-glucuronidase. In addition we incubated one control (non-ethanol-treated)
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liver extract which contained no detectable EtG (Fig. 2.3c) in the presence of β-
glucuronidase to demonstrate that addition of enzyme and overnight incubation do not
cause ethanol to appear in the spectra (Fig. 2.3c,d). This finding demonstrates that (i)
the reaction in Fig. 2.2a,b required the source of the unassigned triplet at 1.24ppm as
a substrate, and (ii) there was no contamination of the β-glucuronidase with ethanol.
Finally, we recorded sequential 400MHz proton spectra at 37◦C (Fig. 2.4a) to demon-
strate the stoichiometry during the enzymatic hydrolysis of EtG to ethanol. By inte-
grating the baseline-corrected signals from ethanol and EtG, and normalizing by the
integral for formate (which had been added as an exogenous concentration reference
(Kriat et al., 1992)), we were able to demonstrate that the sum of [ethanol] + [EtG]
was approximately constant over the 49 hours during which the data were recorded
(Fig. 2.4b). This finding is consistent with the hydrolysis of EtG to form ethanol, and
provides important support for our assignment of the triplet at 1.24ppm to EtG. In ad-
dition, during the hydrolysis of EtG, we were able to observe an increase of glucuronic
acid by monitoring the α-H1 resonance at 5.22ppm. Glucuronic acid exists as α- and
β- anomers in solution, but at 37◦C the residual water signal overlaps with the β-H1
signal at 4.62ppm, and thus the signal from the β anomer cannot be quantified reliably.
During the 49-hour incubation, the increase in signal from the α-H1 proton was several
times greater than the increase in the ethanol signal, when adjusted for the number of
protons contributing to each resonance. Whereas we observed a quantitative increase
in signals from α- and β- anomers of free glucuronate during hydrolysis of methyl glu-
curonide (a positive control, data not shown), it is likely that the large increase in
signal from free glucuronate in liver extracts reflects hydrolysis of glucuronides other
than EtG that were present in liver. Nevertheless, increased signal due to free glu-
curonic acid is expected during hydrolysis of EtG and provides additional confirmation
that our unknown signal is caused by EtG.
As an additional step to confirm our assignment, we searched our 700MHz spectra
for signals due to the β-anomeric proton of EtG. We discovered a doublet at 4.49ppm,
the intensity of which appeared to be correlated to that of the putative EtG triplet at
1.24ppm (Fig. 2.5). Based on the results of peak fitting of these signals in five 700MHz
spectra, the ratio of the triplet to doublet signal is 3.03±0.66, consistent with the
assignment of the doublet to the anomeric proton of EtG. We attribute the variance to
(i) quantification of very small signals on an imperfect baseline and (ii) inconsistencies
in the effect of the presaturation sequence on signals near the water resonance across
different spectra. As an additional confirmation, we analyzed the same doublet in the
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Figure 2.4: Sequential 400MHz proton NMR spectra of a single sample incubated with
β-glucuronidase at 37◦C. Over time the intensity of EtG (triplet, 1.24ppm) decreases
while the intensity of ethanol (triplet 1.19ppm) increases, consistent with hydrolysis of
EtG. The right panel (b) shows the relative concentrations of ethanol and EtG over
time. The sum of ethanol + EtG (triangles) is approximately constant over time, as
would be expected during hydrolysis of EtG to ethanol.
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Figure 2.5: Identification of signal from the EtG anomeric proton. Right and left panels
show expanded regions from the same 700MHz spectra of liver extracts. Visually, the
intensity of the doublet at δ 4.48-4.50ppm (arrow) appears to be correlated to that of
the putative EtG triplet at 1.24ppm. The ratio of areas between the triplet and the
doublet is 3.03±0.66, further supporting the assignment.
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Figure 2.6: Effect of Enzymatic Hydrolysis on Putative EtG Signals. The right and
left panels show expanded regions of 400MHz proton spectra of liver extracts before
(top) and after (bottom) overnight incubation with β-glucuronidase. Signals from the
triplet at 1.24ppm and the doublet at 4.49ppm both decrease on incubation with β-
glucuronidase, supporting the assignment of these signals to the methyl and anomeric
protons of EtG.
400MHz spectra acquired before and after enzymatic hydrolysis. We found that the
doublet, like the putative EtG triplet, decreased after overnight incubation with β-
glucuronidase, supporting the assignment of these signals to the anomeric proton and
methyl protons of EtG, respectively. Finally, a 400MHz proton spectrum of pure EtG
(Fig. 2.7) helped to secure our assignments. The list of resonances is presented in
Table 2.1, and these are completely consistent with our interpretation of the enzymatic
hydrolysis results.
Previous NMR-based metabolomic studies have identified a triplet at 1.24 ppm.
1H shift (δ ) Multiplicity Assignment
1.24 t (J7,8 = 7.1 Hz) 8CH3
3.30 m 3CH
3.52 m 2CH,4CH
3.71 m 7CH2
3.99 m 5CH
4.48 d (J1,2 = 8.0 Hz) 1CH
Table 2.1: List of EtG resonances observed in a 400MHz proton spectrum in D2O at
pH 7.
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Figure 2.7: Spectrum of EtG with assignments.
Teague et al. report the detection of ethyl glucoside in the urine of human volunteers
who had recently consumed rice wine and sake (Teague et al., 2004). Ethyl glucoside,
unlike EtG, is not a metabolite in humans (Teague et al., 2004). Rather, it is the
fourth most abundant constituent of sake (Hayakawa et al., 2000), formed during the
production of this beverage (Mishima et al., 2005). Ethyl glucoside is structurally
similar to EtG, with the exception that the carbonyl is reduced to a methylene group,
and the two new protons give rise to a doublet of doublets at 3.86ppm that is not
present in EtG. The methyl group on ethyl glucoside would give a triplet at nearly the
same chemical shift as the one on EtG (1.24ppm). However, (i) we do not find a doublet
of doublets at 3.86ppm in our 700MHz spectra of liver extracts (data not shown), (ii)
we found evidence of hydrolysis by β-glucuronidase, (iii) we found the signal from an
anomeric proton at 4.49ppm, whereas the anomeric proton of ethyl glycoside resonates
at 4.93ppm, and (iv) ethyl glucoside is not known to be a metabolite of ethanol. Thus,
we conclude that EtG rather than ethyl glucoside is the source of the triplet observed
in our liver samples.
Correct attribution of NMR spectral peaks to the molecules in a sample that give
rise to these signals is crucial to the proper interpretation of experimental results.
Nevertheless, the process of signal assignment is usually the most time-consuming and
error-prone aspect of data analysis. For example, a previous 400MHz 1H NMR study
of liver extracts from ethanol-treated rats (36% ethanol liquid diet for 1.5 months)
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attributed a triplet at 1.21ppm (referenced relative to the acetate singlet at 1.92ppm
at pH 7.5) to residual ethanol that had not evaporated during lyophilization (Ling and
Brauer, 1991), yet visual examination of the published spectra reveals the presence of
weak signals (possibly a triplet) upfield of the triplet that the authors concluded was
due to ethanol. While it is possible that the assignment was correct, this pattern of a
weak triplet (ethanol) immediately upfield from a stronger one (EtG) (evident from our
700MHz data, Fig.1a) suggests that the triplet previously observed is consistent with
EtG. Therefore, taken together, the data we present suggest that EtG is detectable
by proton NMR spectroscopy in liver of ethanol-exposed animals, that EtG may in
fact have been detected (though unrecognized) in previous studies, and that signals
from this biomarker for ethanol administration will likely be encountered in future
NMR studies of liver. Other studies have found EtG in plasma, urine, hair and other
tissues (Wurst et al., 2003) suggesting EtG produced in liver is distributed throughout
much of the body, where it may persist for some time. Should technical advances
in NMR spectroscopy (discussed above) improve the sensitivity and/or dynamic range
such that detection of 10-600µM EtG (2.2-132 mg/L) in urine and plasma (Wurst et al.,
2003) becomes straightforward, direct analysis by NMR may become an inexpensive,
simple, fast, and unbiased alternative to the use of derivatization followed by GC/MS
to detect and quantify EtG or other xenobiotics. This study highlights the benefits of
NMR spectroscopy with minimal pre-selection of analytes as an unbiased method for
the discovery of novel metabolites. Though other analytical methods certainly possess
superior sensitivity, they require prior knowledge of analytes, and therefore EtG (an
unexpected compound) would likely have gone undetected. NMR spectroscopy not only
alerted us to the presence of an unexpected compound, but also provided structural
information that aided us in its identification.
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Chapter 3
Integrated Multi-organ Analysis of
the Effect of Ethanol on Liver,
Brain and Serum Metabolites
3.1 Introduction
Ethanol is a unique and widely used drug that is typically consumed in large amounts
for pharmacologic effect. The primary route of elimination is hepatic oxidation to
acetate. A single dose of ethanol perturbs hepatic regulation of glucose and causes
release of large amounts of acetate into the blood. Acetate is a two-carbon fatty acid
that can be oxidized via the TCA cycle in many tissues. Of particular interest to us,
acetate is metabolized in astrocytes within the brain (Zwingmann and Leibfritz, 2003),
and may play a role in intoxication (Israel et al., 1994) and dependence to ethanol
(Derr et al., 1981).
Ethanol oxidation proceeds via cytosolic NAD-dependent alcohol dehydrogenase
(ADH) and via the NADPH-dependent microsomal ethanol oxidizing system (MEOS),
yielding acetaldehyde (Eckardt et al., 1998). Acetaldehyde is oxidized to acetate by
mitochondrial aldehyde dehydrogenase (ALDH), and most of the resulting acetate is
released from the liver into the blood (Jucker et al., 1998). The challenge for the liver
during this process is to maintain an adequate supply of reduced cofactors for these
enzymes (Eckardt et al., 1998), while performing its usual regulatory and synthetic
functions.
Numerous reports have demonstrated the utility of an NMR-based metabolomic ap-
proach coupled with pattern recognition (PR) for the analysis of complex biochemical
responses to exogenous toxins in experimental animals (Nicholson et al., 1999; Solanky
et al., 2003), and for the classification of human patients on the basis of their biochem-
ical state (Brindle et al., 2002). Prior to the advent of metabolomics, 400MHz proton
NMR spectroscopy of rat liver extracts revealed that chronic ethanol increased acetate
and beta-hydroxybutyrate, and decreased alanine (Ling and Brauer, 1991). In compar-
ison, however, our study benefits from (i) analysis of multiple tissues (liver, serum and
brain), (ii) the availability of a 700MHz spectrometer that affords substantial gains in
resolution and sensitivity, (iii) the availability of recent literature describing assignments
of various metabolites in NMR spectra, and (iv) the advent of metabolomic methods
for comprehensive spectral analysis. We have chosen to apply a multi-compartment
metabolomic analysis to gain additional insight into the metabolic processes affecting
multiple organs during intensive ethanol intake. In contrast to the approach adopted in
many metabolomic studies, we have attempted to quantify as many individual metabo-
lites as possible in addition to submitting spectral data to unsupervised analysis for
validation of the quantitative NMR analysis. By correlating data on multiple organs,
we increase our ability to develop a comprehensive understanding of the system-wide
metabolic perturbation caused by ethanol, and to identify testable hypotheses for future
confirmatory studies.
3.2 Methods and Materials
3.2.1 Animal Handling Procedures and Sample Collection
All protocols in this study were approved by the Institutional Animal Care and Use
Committee and were in accordance with National Institute of Health regulation for the
care and use of animals in research. Adult male Sprague-Dawley rats (275-325g) were
treated with a modified 4-day-binge-ethanol protocol as previously described (Obernier
et al., 2002a). A 15% (w/v) ethanol Reitz High Fat diet was used with an appropri-
ate isocaloric control. Rats were given an initial dose (5g/kg, 25%w/v, in a vehicle
of nutritionally complete diet) with subsequent doses determined using a six-point be-
havior scale (Majchrowicz, 1975). Control animals received a diet equal to the average
of all ethanol- treated animals. Prior to the start of experiments, half of the animals
were treated with the anti-oxidant butylated hydroxytoluene (BHT) (120mg/kg/day
in corn oil, i.g.) for 4 days. All animals had free access to water throughout the ex-
periment. This protocol produces physical dependence to ethanol (Majchrowicz, 1975)
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and induces neuropathology modeling that found in human alcoholics (Obernier et al.,
2002a). Blood ethanol concentration (BEC) was measured using electrochemical de-
tection of an enzymatic reaction with an Analox Instruments model GM-7 analyzer
(Analox Instruments, MA). Ethanol groups had mean BECs around 300 mg/dl (range
250-375 mg/dl). Within one hour after the last treatment, all animals were sacrificed,
and liver samples were collected and stored at -80◦C until further analysis.
In a separate experiment, rats were randomly selected to receive ethanol (5g/kg,
20% w/v in water, i.g.), water (i.g.), or sucrose calorically matched to the ethanol
(i.g.). Three hours after dosing, rats were anesthetized with pentobarbital. Following
the onset of surgical anesthesia, an abdominal incision exposed the liver and inferior
vena cava (IVC). A blood sample (2-4ml) was collected from the IVC and allowed to
clot on ice. Next, each animal was decapitated and the skull immediately immersed
in liquid nitrogen with agitation in the liquid to hasten the freezing process, while a
small piece of liver (1-2g) was quickly removed, wrapped in aluminum foil, and frozen in
liquid nitrogen. The time from surgical anesthesia to decapitation was approximately 90
seconds; the time between the start of blood withdrawal and decapitation was less than
45 seconds; the time from decapitation to placing the liver sample in liquid nitrogen
was less than 30 seconds. Clotted blood was centrifuged, and serum was removed and
stored along with liver and skull samples at -80◦C until further analysis.
After the experiment, we became aware that the vehicle for the pentobarbital con-
tained 50% water, 40% propylene glycol, and 10% ethanol (see below). Nevertheless,
because this dose (<0.2g/kg) was (i) substantially smaller than the 5g/kg dose given
to the ethanol-treated group, (ii) present only for 5 minutes before sacrifice, and (iii)
would, if anything, tend to minimize differences between groups, creating a more strin-
gent challenge for the metabolomic approach, we deemed it appropriate to proceed with
the analysis.
3.2.2 1H NMR Spectroscopic Analysis
Frozen tissues were removed from the -80◦C freezer and placed in liquid nitrogen.
Tissues were then pulverized with a stainless steel mortar and pestle and extracted with
perchloric acid (Fan et al., 1986). Lyophilized extracts were dissolved in a stock solution
containing 12.9mM sodium formate and 1.4mM 3-(trimethylsilyl)propionic-2,2,3,3-d4
acid (TSP), adjusted to pH 7.0 (pD 6.6) with DCl or NaOD prior to NMR analysis.
Proton spectra were acquired on a Varian Inova 700MHz spectrometer in fully relaxed
43
mode (duty cycle = 45s), at 25 C, with 1-2s presaturation of water protons immediately
prior to a 90 excitation pulse. Other parameters were: 16 transients, spectral width
8600Hz, 64k data points.
Serum samples were prepared by thawing from -80◦C in a microcentrifuge at 13000
rpm for 4 minutes, after which 500µL of serum was mixed with 250µL of stock solution
(see above). When less than 500µL of serum was available, additional stock solution
was added to make 750µL total, and the volumes were recorded. 700µL of the resulting
mixture was transferred to a 5mm NMR tube for analysis. 700MHz proton spectra
were acquired using the parameters given above.
In many cases, spectral assignment of well-resolved signals was accomplished with
reference to appropriate literature (Waters et al., 2005; Nicholson et al., 1995; Fan, 1996;
Govindaraju et al., 2000). In some cases, pure compounds were added to the original
samples and additional spectra were collected on a Varian Inova 400MHz spectrometer.
Parameters were identical to those used to collect the original spectra, except that the
spectral width was 4800Hz.
Time domain data were zero-filled to 128k points, Fourier transformed, phase cor-
rected, and baseline corrected for DC offset. Tissue extracts were referenced to TSP (δ
0ppm), and serum spectra were referenced to formate (δ 8.46). Where possible, peak
assignments were made, and well-resolved resonance were integrated, allowing absolute
quantification of metabolites in serum (in units of mM) and tissue (in units of mmol/kg
wet weight).
3.2.3 Data Reduction and Principle Components Analysis
Spectral data were reduced from 128k to 245 points by integrating the region from δ 0.2-
10ppm in segments 0.04ppm wide. The bins containing water (δ 4.68-5.12), propylene
glycol (δ 1.12-1.16), and formate (δ 8.40-8.52) were excluded from analysis. In serum
samples, ethanol was not removed by lyophilization; thus, in these samples, bins con-
taining ethanol (δ 1.16-1.24 and δ 3.60-3.72) were excluded as well. The remaining bins
were submitted to unsupervised analysis. Data were mean centered (Craig et al., 2006)
and the principal components (PCs) computed using custom software written in the
Matlab (The MathWorks, Inc., Natick, MA) programming environment(PC Nicholas).
The PCs are a new set of orthogonal basis vectors: linear combinations of the origi-
nal spectral data such that the first PC falls along the direction of greatest variance
in the original data, the second is orthogonal to the first, and is oriented along the
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direction of greatest remaining variance, and so forth (Nicholson et al., 1999). Thus,
plotting the original data projected onto PC1 vs PC2 often provides an informative
two-dimensional representation of the underlying ( 200 dimensional) data, with differ-
ent treatment groups segregating themselves in the new PC coordinates (Lindon et al.,
2004). Moreover, analysis of the PC vectors affords the opportunity to determine
which spectral regions contributed to the separation of spectra different among treat-
ment groups, thereby providing insight into the biochemical differences and possible
mechanisms for toxicity (Nicholson et al., 1999).
3.2.4 Statistical Analysis
In all charts, data are plotted as mean ± standard deviation, and the number of ani-
mals in each group is indicated. When comparing means between different treatment
groups, a t-test (two tailed, unequal variance) was used to assess statistical signifi-
cance. A p-value of less than 0.05 was deemed significant. We have opted to present
p-values without correction for multiple comparisons for the following reasons. The first
objection concerns the data itself: many of the metabolites quantified in this report
are linked via their participation in known biochemical networks, and therefore con-
centrations of many are not statistically independent; the commonly-used Bonferroni
correction is therefore inappropriately conservative (Bland and Altman, 1995). The
second objection concerns study design: by their nature (i.e. large number of measured
parameters, small number of samples), metabolomic studies are designed to generate
hypotheses rather than to test preexisting ones. For this type of study, an optimal
multiplicity correction method has not been universally accepted (Sankoh et al., 1997),
and the approach of presenting the uncorrected p-values has been advocated instead
(Bender and Lange, 1999).
3.2.5 Biochemical Interpretation
To the extent possible, biochemical perturbations due to ethanol exposure were inter-
preted within the framework of the known chemical reactions of intermediary metabolism.
In addition to standard texts, the KEGG database (Kanehisa et al., 2006) was a useful
resource for ascertaining metabolic relationships between various molecules.
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3.3 Results
3.3.1 1H Spectroscopic Analysis of Serum
1H NMR spectra of serum revealed changes in many metabolites after a single dose of
ethanol or sucrose, compared to water (Fig 3.2, 3.1). In comparison to water, sucrose
treatment caused an 89% decrease in acetoacetate (p=0.00092), a 1.8-fold increase in
glucose (p=0.00020), and non-significant trends toward increased lactate and acetate.
Ethanol, in comparison to water, caused a 57% decrease in lactate (p=0.0073), a 62%
decrease in alanine (p=0.00066), a 2-fold increase in acetate (p=0.0062), a 3-fold in-
crease in acetoacetate (p=0.000074), and had no effect on glucose. In comparison to
animals that received sucrose, ethanol caused lactate to decrease 76% (p=0.040), ala-
nine to decrease 62% (p=0.0015), glucose to decrease 39% (p=0.0021), and acetoacetate
to increase 28-fold (p=0.000079). In the ethanol-treated animals, serum ethanol con-
centration 3 hours after dosing was 77±6mM. Ethanol (6±2mM) and propylene glycol
were discovered in a 1:4 ratio in the serum of sucrose- and water-treated animals since
these were components of the vehicle for the pentobarbital anesthetic (see methods).
Due to spectral overlap with the very large signal from ethanol, beta-hydroxybutyrate
could not be quantified.
3.3.2 1H Spectroscopic Analysis of Liver
Ethanol-induced perturbations in several hepatic metabolites were evident in 1H NMR
spectra of extracts (Fig. 3.3, 3.4). In comparison to water controls, single-dose-
ethanol animals showed a 72% decrease in alanine (p=0.038), a 1.7-fold increase in
acetate (p=0.011), and non-significant trends towards decreased lactate and increased
beta-hydroxybutyrate. Compared to sucrose controls, in single-dose-ethanol animals
we found alanine decreased 90% (p=0.0016), lactate decreased 80% (p=0.0040), and
glucose decreased 60% (p= 0.0016), while beta-hydroxybutyrate increased 5.1-fold
(p=0.011). Hepatic acetate was comparable between ethanol and sucrose groups, and
succinate was not affected by ethanol or sucrose treatment.
Turning our analysis to the binge ethanol groups, we found that binge ethanol
decreased hepatic alanine (92%, p= 0.00018), lactate (89% (p= 0.000083), and succi-
nate (60%, p= 0.000063), whereas it increased acetate 9-fold (p= 0.00028), and beta-
hydroxybutyrate 15-fold (p= 0.023). Overall, the binge control and binge control+BHT
groups were similar; the BHT pre-treated group showed modest decreases in lactate
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Figure 3.1: 700MHz proton spectra of serum collected from a control animal (a), 3
hours after a single dose of ethanol (b), and 3 hours after dosing with sucrose (c).
Large signals from ethanol are evident in the ethanol-treated animals, so large in fact
that the satellite peaks due to natural abundance (1.1%) 13C are visible. We found that
ethanol decreases lactate and alanine signals, while increasing acetoacetate and acetate,
compared to dosing with water. As discussed in methods, the sucrose and water control
groups were also inadvertently administered a small dose of ethanol (<0.2g/kg, i.p.) in
the vehicle for the pentobarbital anesthetic, and signals from ethanol are seen in (a) and
(c). Key: as in 3.3, with the addition of Aca, acetoacetate; Cit, citrate; Nac1/Nac2,
composite acetyl signals from α1-acid glycoprotein (Waters et al., 2005); S1/S2,
13C
satellites of ethanol.
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Figure 3.2: Effect on selected serum metabolites 3 hours after i.g. administration of
ethanol (5k/kg), water, or sucrose. Lactate and alanine decreased at least 2-fold in
ethanol-treated animals in comparison to animals treated with water or sucrose. Ac-
etate increased 2.1-fold in ethanol-treated animals versus water-treated animals, but
not in comparison to sucrose-treated animals. It is likely that inadvertent administra-
tion of ethanol (in the vehicle of the pentobarbital solution, see methods) to all animals
just before sacrifice gave falsely high acetate levels in sucrose and water groups. Serum
glucose was 1.6-fold lower in ethanol-treated animals than in sucrose controls.
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Figure 3.3: 700MHz proton spectrum of liver extracts from (a) control, (b) 3 hours after
a single dose (5g/kg) of ethanol, (c) 4 day binge ethanol treatment, (d) 4 day binge
ethanol + BHT pre-treatment, (e) 3 hours after sucrose. Both acute and binge ethanol
treatment decrease hepatic Lac and Ala, and increase Ace and 3HB. EtG is present 3
hours after a single dose of ethanol, and is greater in the binge-ethanol treated group,
whereas in the binge ethanol + BHT group, EtG is scarcely visible. Key: 3HB, beta-
hydroxybutyrate; Ace, acetate; α-Glc, α-glucose; Ala, alanine; Bet, betaine; β-Glc,
β-glucose; Cho, choline; Cr, creatine; EtG, ethyl glucuronide; Gln, glutamine; GPC,
glycerophosphorylcholine; Glu, glutamate; GSH, glutathione; Ile, isoleucine; Lac, Lac-
tate; Leu, leucine; PC, phosphocholine; PG, propylene glycol; Succ, succinate; TMAO,
trimethylamine-N-oxide, Thr, threonine; Val, valine.49
(31%, p=0.043) and alanine (41%, p=0.019). For the endogenous metabolites shown
in Figure 3.4, binge-ethanol and binge-ethanol + BHT groups showed no significant
differences, indicating a lack of effect of BHT pre-treatment on ethanol’s perturbation
of these metabolites.
Comparing the binge and single-dose groups (Fig. 3.4), the most striking difference
is that succinate levels were lower in the single-dose animals than the binge animals
(e.g. comparing binge control to single-dose water shows a 94% decrease, p=0.000069).
Additionally, acetate levels were increased in water- and serum-treated animals rela-
tive to binge controls, and the water-treated animals had lower hepatic alanine (77%,
p=0.000065) and lactate (75%, p=0.000093). Thus, both acute and binge ethanol de-
crease lactate and alanine, and increase acetate and beta-hydroxybutyrate. Taking
sucrose treatment and binge control diets to be indicative of the fed state, it appears
that overnight fasting and dosing with water also decreases lactate and alanine, but
not as much as ethanol. Compared to the fed state, ethanol decreases hepatic glucose
levels.
Careful analysis of the spectra revealed an unexpected triplet at 1.24ppm in ethanol-
treated animals but not in diet controls. We ruled out the possibility that this signal
originated from residual ethanol that had not evaporated during lyophilization (Ling
and Brauer, 1991), assigned the signal to ethyl glucuronide (EtG) as described in §2,
and quantified it (Fig. 3.5). EtG is undetectable in livers from animals that received no
ethanol, but within 3 hours of a large dose of ethanol, hepatic levels rise to the 2mmol/kg
range, and remain elevated during the 4-day binge. Interestingly, pretreatment with
BHT caused a 90% decrease (p =0.008) in EtG during 4 days of binge ethanol treatment.
Thus ethyl glucuronide is a unique metabolite found only with ethanol administration
that is reduced by BHT.
A strong singlet at 3.28ppm in liver spectra (Fig 3.3) was investigated. We analyzed
spectra after addition of betaine and TMAO, two metabolites commonly assigned to
signals in this region (Coen et al., 2003). The consistent finding was that the large
singlet in our original spectra was due to betaine, and that the signal from TMAO,
if present, was generally an order of magnitude smaller (Fig. 3.6). Having identified
the signal as originating from betaine, we quantified it and compared results across
treatment groups. Betaine did not appear to be altered by a single dose of ethanol, but
both binge-ethanol and binge-ethanol + BHT showed a trend of decreased betaine with
binge-ethanol + BHT being significantly less than binge-control + BHT (p=0.0033) ,
but not binge control. (Fig. 3.7). Thus, BHT seems to elevate liver betaine, a single
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Figure 3.4: Effect of ethanol on selected metabolites in liver quantified by proton
NMR spectroscopy of tissue extracts. In comparison to diet controls, hepatic lac-
tate decreased in all animals that received ethanol (9-fold for binge-ethanol, 5-fold for
binge-ethanol+BHT, and 5-fold for single dose ethanol), as did alanine (13-fold for
binge-ethanol, 7-fold for binge-ethanol+BHT, and 10-fold for single-dose ethanol) and
glucose (32% decrease for binge-ethanol, 32% for binge-ethanol+BHT, 60% for single
dose). Succinate decreased approximately 60% in binge ethanol treated animals (with
or without BHT) versus binge controls. However, succinate was greater in all binge
groups than single-dose animals, perhaps due to differences between the liquid diet and
standard rat chow. Beta-hydroxybutyrate increased in all animals treated with ethanol
(15-fold in binge groups, and 5-fold in the single dose group). Acetate increased 9-fold
in binge ethanol animals versus binge controls; in the binge-ethanol+BHT group, the
trend was apparent, but it was not statistically significant due to large variance in this
group’s acetate levels. Acetate levels in the single-dose ethanol group were comparable
to the binge-ethanol group, however the sucrose-treated animals showed elevated ac-
etate levels also due to the inadvertent administration of ethanol just before sacrifice
in the anesthetic vehicle (see methods).
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Figure 3.5: Quantification of ethyl glucuronide (EtG) in liver extracts via 700MHz 1H
NMR spectroscopy. EtG reaches ∼ 2mmol/kg in liver within 3 hours after a single
dose of ethanol, and remains elevated during binge ethanol treatment. Pre-treatment
with BHT caused a 9-fold reduction in EtG (p<0.01 versus binge-ethanol group), pos-
sibly because BHT competed against ethanol for access to activated glucuronide (see
discussion).
dose of ethanol has no effect, and binge ethanol showed a trend toward a decrease in
betaine.
We attempted to collect a 1H NMR spectrum of pure BHT in order to assign any
signals from this molecule in our liver extracts. However, we found that BHT was so
hydrophobic that at neutral pH and room temperature we could not dissolve enough
in D2O to detect any signal. Thus our liver spectra from the BHT animals likely do
not contain any signals from BHT.
3.3.3 1H Spectroscopic Analysis of Brain
Few changes were evident in the signals from brain metabolites (Fig. 3.8). Though
signals were well-resolved, and many metabolites were quantified, no clear trends in
metabolite concentrations were detectable 3 hours after a single dose of ethanol.
3.3.4 PC Analysis of Liver NMR spectra
As a first pass, we performed PCA on data from all 7 groups of liver extracts (Fig.
3.9). Separation along PC1 (which explained 46.9% of the variance in this data set)
primarily differentiated single-dose from binge groups, irrespective of ethanol treatment
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Figure 3.6: Assignment of betaine and TMAO in 400MHz 1H NMR spectra of liver
extracts. Spectra were acquired before addition of exogenous material (a), after sequen-
tial addition of TMAO (b) and then betaine (c) in order to assign the large singlet at
3.29ppm in the original spectrum (a, see also Fig 1). Clearly the original signal in (a)
is not consistent with TMAO, but is consistent with betaine. Additional confirmation
of the assignment is provided by the methylene protons of betaine which produce the
singlet at 3.94ppm. TMAO, if present in the original extract before addition of pure
compounds (a), is at least an order of magnitude less abundant than betaine.
Figure 3.7: Effect of BHT and ethanol on betaine concentration in liver. A single dose
of ethanol appears to have no effect on betaine concentration. BHT pre-treatment
elevates betaine 2.8-fold versus binge control without BHT (p = 0.020), whereas binge
ethanol+BHT decreases betaine 3.3-fold (p=0.0033) versus control+BHT. There was
a trend towards decreased betaine in the binge-ethanol group that received no BHT,
but it was not statistically significant.
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Figure 3.8: 700MHz proton spectra of brain extracts (a) control, (b) 3 hours after a
single dose of ethanol (5g/kg), (c) 3 hours after a dosing with sucrose. Lactate and
alanine appear to be increased in the sucrose-treated brain, but overall, the spectra are
quite similar for the three groups. Abbreviations: as in Fig. 3.1, with the following ad-
ditions: Asp, aspartate; GABA, gamma-aminobutyric acid; mIns, myo-inositol; NAA,
N-acetyl aspartate; PCr, phosphcreatine; Tau, Taurine.
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Figure 3.9: PC analysis of 700MHz proton NMR spectra of all livers (binge and single-
dose analyzed simultaneously). The three-dimensional scores plot (a) shows good sepa-
ration of binge-ethanol-treated animals (with and without BHT pretreatment) from the
other animals along PC3, and to a lesser extent along PC2. A two-dimensional plot of
the data projected onto PC2 vs PC3 (b) demonstrates clear separation of binge-treated
animals along PC3, with single dose ethanol animals showing a trend toward separa-
tion. The loadings plots are given (c-f); annotations, when given as single numbers,
refer to lower bound of a 0.04ppm wide spectral region (see methods). Key: as in Fig.
3.3.
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Figure 3.10: PC analysis of liver samples for binge-ethanol and binge-control groups
(a), separately from single-dose groups (b). By separating the analysis in this way, the
variance due to ethanol treatment is separated from differences in diet and other factors
that obscured the effect of ethanol treatment in Fig. 3.9. Loading plots indicating the
spectral regions that contribute to separation of various treatment groups: (c) binge
PC1, (d) binge PC2, (e) single dose PC1, (f) single dose PC2.
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(data not shown). However, binge-ethanol groups (with and without BHT) separated
from others along PC2 (16.7% of variance) and PC3 (15.6% of variance), with the single
dose ethanol group showing some separation along PC3. Loadings plots for PC2 and
PC3 (Fig 3.9c,d) indicate that choline-containing compounds (δ 3.20-3.24), betaine (δ
3.24-3.28, δ 3.92-3.96), lactate (δ 1.32-1.36,δ 4.08-4.16), alanine (δ 3.20-3.24), and EtG
(δ 1.20-1.24) were among the largest contributors to separation of the binge-ethanol-
treated animals.
For an additional level of analysis, we performed PCA on the binge and single-dose
groups separately (Fig. 3.10). By separating the analysis in this way, the variance
due to ethanol treatment is separated from differences in diet and other factors that
obscured the effect of ethanol treatment in Fig. 3.9. For binge animals (Fig. 3.10a),
there was relative separation of the control diet versus control + BHT groups, whereas
the binge-ethanol and binge-ethanol + BHT groups co-mingle in PC space. Loadings
plots (Fig. 3.10c,d) indicate that choline-containing compounds and betaine made the
largest contribution to PC1, with lactate, glutamate (δ 2.12-2.20), and EtG also con-
tributing. These signals also contributed to PC2, with the spectral regions containing
unresolved glucose and amino acids (δ 3.3-4.0) also making a contribution.
Single-dose groups show large separation in the scores plot (Fig. 3.10b), with PC1
differentiating ethanol and sucrose, and PC2 separating water from the other groups.
The loading plots reveal that once again betaine, lactate, alanine, EtG and sugars were
significant contributors to the PCs. In comparison to the binge animals, EtG made a
relatively larger contribution to both PC1 and PC2 in the single dose group.
3.3.5 PC Analysis of Serum NMR Spectra
Single-dose animals that received ethanol separated dramatically from water and su-
crose groups along PC1 (Fig. 3.11a). Water and sucrose groups show separation along
the PC2 axis. Because of the decision not to use relaxation editing (Tang et al., 2004)
to suppress signals from proteolipids, the spectra contain many broad components, es-
pecially in the 0.5-3.0ppm region, and these are reflected in the loadings plots (Fig.
3.11c,d). Loadings plots revealed that PC1 contained signals from lactate, glucose (δ
3.20-3.28,δ 3.44-3.48,δ 3.52-3.56, δ 3.88-3.92,δ 5.20-5.28), and Nac1 (δ 2.04-2.08) and
Nac2 (δ 2.12-2.16); with respect to water and sucrose controls, ethanol-treated ani-
mals showed decreases in all of these compounds (negative PC1 values). PC2 separates
groups based on an inverse relationship between lactate and Nac1,2, with an additional
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Figure 3.11: PC analysis of single dose serum (a) and brain (b). Serum shows clear sep-
aration of alcohol-treated animals (triangles) from water- (circles) and sucrose-treated
animals (squares) along PC1, with some separation of water and sucrose treated ani-
mals along PC2. Brain shows some separation of groups along PC1, but PC2 appears to
be less informative. Loadings plots for serum PC1 (c) and PC2 (d), and brain PC1 (e)
and PC2 (f) indicate which spectral regions contribute to the classification of various
groups.
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contribution from the signal at δ 0.84-0.88. On this basis, sucrose-treated animals
appear to have a large Lac/Nac1,2 ratio (positive PC2 values) whereas water-treated
animals have a low Lac/Nac1,2 ratio (negative PC2 values).
3.3.6 PC Analysis of Brain NMR Spectra
PC analysis of brain spectra revealed incomplete separation of the ethanol, water, and
sucrose groups in the scores plot (Fig. 3.11b), though some trends are evident. The
mean PC2 value for the ethanol group is lower than either of the other two groups.
The water-treated group is tightly clustered in PC1, but shows large spread in PC2.
The loadings plots (Fig. 3.11e,f) reveal that lactate was the largest contributor to
PC1 (which explained 45.9% of the variance), followed by creatine+phosphocreatine (δ
3.96-4.00). PC2 showed two dispersive (”one up, one down”) pairs indicative of signals
(glutamate + glutamine at δ 3.80, and taurine+myoinositol at δ 3.32) whose frequency
drifted at least one bin width (0.04ppm, 28Hz) across the data set. Combining these
pairs of buckets into a single bin (width 0.08ppm) and repeating PC analysis did not
yield appreciable improvement in the separation of the groups in the scores plot (data
not shown).
3.4 Discussion
3.4.1 Energy Metabolites in Liver and Serum
Our findings shed light on the effects of ethanol on gluconeougenesis and how lactate
and alanine participate in these effects. Our finding that both acute and binge ethanol
decreased lactate and alanine in rat liver and in serum are consistent with previous
studies (Ling and Brauer, 1991). There exists, however, some debate about the ef-
fect of ethanol on glucose regulation. Cohen et al. found in perfused mouse livers
that acute ethanol stimulates hepatic utilization of [3-13C] alanine for gluconeogenesis
(Cohen et al., 1979), and they explained this result on the basis that ethanol oxida-
tion increases the NADH/NAD ratio. An earlier study also found in perfused livers
that ethanol stimulated gluconeogenesis from alanine and increased consumption of
lactate (Williamson et al., 1969). However, Krebs himself reported that ethanol in-
hibits gluconeogenesis (Krebs et al., 1969). More recently, Mokada et al. reported
that incorporation of 14C from lactate into glucose in perfused rat liver was inhibited
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Figure 3.12: Metaboic perturbations in liver during ethanol metabolism. Bold ar-
rows indicate observed changes in hepatic metabolite concentrations in response to
binge-ethanol exposure. Ethanol oxidation to acetaldehyde via cytosolic ADH increases
cytosolic NADH, and mitochondrial oxidation of acetaldehyde to acetate via ALDH in-
creases intramitochondrial NADH. The elevated acetate and NADH/NAD levels stim-
ulate gluconeogenesis, initially by increasing flux through pyruvate carboxylase (PC;
EC 6.4.1.1). Subsequently, lactate and alanine are converted to pyruvate via alanine
transaminase (AT; EC 2.6.1.2 ) and lactate dehydrogenase (LD; EC 1.1.1.27 ). Reduced
alanine levels remove inhibition of pyruvate kinase (PK EC 2.7.1.40), converting phos-
phoenolpyruvate (PEP) formed in response to the high NADH/NAD ratio to pyruvate,
and thus creating a futile cycle.
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up to 80% by ethanol (Mokuda et al., 2004), and they point out that hepatic regula-
tion of glucose is different in the fed versus the fasted state. Our data are consistent
with consumption of lactate and alanine, but we find no evidence of increased glu-
cose production (Fig. 3.4, Fig. 3.2) following acute or binge ethanol administration; if
anything, the data suggest the opposite: decreased glucose after binge ethanol adminis-
tration (Fig. 3.4), and no increase in hepatic glucose following a single dose of ethanol.
Figure 3.12 shows a possible mechanism wherein elevated NADH initially stimulates
gluconeogenesis: flux through pyruvate carboxylase (PC) and phosphoenolpyruvate
carboxykinase (PEPCK) increase, and gluconeogenic precursors (lactate and alanine)
replenish the pyruvate that is consumed. Later, however, decreased alanine levels re-
move inhibition of pyruvate kinase (PK) (Llorente et al., 1970), leading to a futile cycle
from pyruvate to oxaloacetate to phospoenolpyruvate (PEP), and then back to pyru-
vate. One may explain the apparently contradictory results of the studies mentioned
above by the observation that decreased intracellular alanine during ethanol oxidation
is critically important in the regulation of gluconeogenesis. Whereas alanine is rapidly
depleted during ethanol oxidation in vivo (Fig. 3.4), Cohen et al. supplied alanine in
the perfusate, so that intracellular alanine was maintained even during ethanol oxida-
tion. Without a decrease in intracellular alanine, PK remained inhibited, and PEP was
used for gluconeogenesis, avoiding the futile cycle. Presumably, when lactate rather
than alanine was supplied in the perfusate (Mokuda et al., 2004), alanine was depleted
(as it is in vivo), and gluconeogenesis was short-circuited by increased PK activity.
Though our explanation appears to have resolved the discordant findings, additional
studies with labeled tracers are required to prove the operation of a futile cycle during
ethanol metabolism. An approach similar to the one used by Petersen et al. (Petersen
et al., 1994) might be appropriate, although the preceding discussion highlights the
importance of selecting tracer molecules that do not directly modulate the activities
of the enzymes under study. Therefore, labeled lactate, perhaps in conjunction with
other molecules, may be a better choice than alanine for this purpose. Regardless, our
studies suggest that in vivo ethanol does not stimulate gluconeogenesis in liver.
We found that ethanol decreased lactate, whereas an entirely different perspective
on hepatic lactate metabolism during ethanol exposure was presented by Lieber et
al. who report that the elevated NADH/NAD ratio during ethanol oxidation caused
conversion of pyruvate to lactate in hepatocytes in order to regenerate reduced NAD
cofactors in the cytosol (Lieber et al., 1962) where AHD is active (Eckardt et al.,
1998). According to this view, the lactate would be released into the blood where
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hyperlactecemia would inhibit excretion of uric acid in the kidney, thus explaining
the association between alcohol consumption and gout (Lieber et al., 1962; Lieber,
1965). Despite the conceptual appeal of this explanation (which has been cited in
reviews published as recently as 2005 (Yamamoto et al., 2005)), it is at variance with
our finding of decreased lactate in both liver and blood after both acute and chronic
ethanol exposure. We note that the original finding of increased blood lactate after
ethanol infusion (Lieber et al., 1962) was based on a colorimetric assay that relied
upon the conversion of lactate to acetaldehyde by heating in concentrated sulfuric acid
(Barker and Summerson, 1941). Given that blood ethanol levels were in the 200-
300 mg% range (44-65mM) in Lieber et al’s study (Lieber et al., 1962), only a small
fraction of this ethanol converted to acetaldehyde during the procedure would cause
falsely elevated estimates of serum lactate levels. We believe this flaw in the original
assay is the most likely explanation for the discordant findings, and that ethanol in fact
causes lactate to decrease in both liver and serum.
Another endogenous energy metabolite that may be involved in the pathway shown
in Fig. 3.2 is succinate. The difference in hepatic succinate levels between the binge
group and the single-dose group may perhaps reflect differences in the liquid diet that
the binge animals received, versus rat chow that other animals were fed. Within the
binge group, the decrease in hepatic succinate due to ethanol may reflect operation of
the mechanism proposed in Figure 3.2. Specifically, if flux of oxaloacetate through phos-
phoenolpyruvate carboxykinase (PEPCK) versus citrate synthase (CS) was increased,
as might be expected by the elevated NADH/NAD ratio during ethanol oxidation
(see above), the net result would be increased conversion of succinate to oxaloacetate,
and decreased formation of succinate. Though speculative, this explanation is consis-
tent with the available data and known mechanisms of biochemical regulation for the
pathways involved. Further experiments are required to clarify ethanol’s effect on the
PEPCK/CS ratio for oxaloacetate and the impact on succinate.
Effect of Inadvertent Ethanol Dosing in Control Animals
The trend toward increased acetate in liver and serum (Fig. 3.3,3.4, 3.1,3.2) are con-
sistent with the oxidation of ethanol to acetate in the liver, and the release of the 90%
or more of the ethanol-derived acetate into the blood (Jucker et al., 1998). Unfortu-
nately, the single-dose animals, for which serum and liver were collected simultaneously,
inadvertently received ethanol as a component of the vehicle for the pentobarbital anes-
thetic, and therefore displayed blood acetate levels greater than the 0.2-0.3mM expected
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in the absence of ethanol (Carmichael et al., 1991). Nevertheless, the trends toward
increased acetate in serum of ethanol-treated animals are still evident (Fig. 3.2), and
in the liver, if the binge-control values (Fig. 3.4) are taken as representative of the
baseline state, the effect of a single dose is clearly to increase acetate several-fold. In-
creased serum acetate could affect metabolism in a number of tissues and suggests that
although liver metabolizes much of the ethanol, acetate produced from ethanol could
alter metabolism throughout the organism.
Ketone Body Formation
The effect of ethanol on ketone body formation can be seen in the increase in beta-
hyroxybutyrate in the liver (Fig. 3.4) and acetoacetate in the serum (Fig. 3.2). It is
likely that these molecules represent a means for the liver to dispose of the surfeit of
ethanol-derived acetate via the following mechanism. In a reaction catalyzed by acetyl-
CoA C-acetyltransferase (EC 2.3.1.9), two molecules of acetyl-CoA condense to form
acetoacetyl-CoA that is converted to acetoacetate via 3-ketoacid CoA-transferase (EC
2.8.3.5) (Kanehisa et al., 2006). Subsequently, acetoacetate can be converted to beta-
hydroxybutyrate by beta-hydroxybutyrate dehydrogenase (EC 1.1.1.30), regenerating
one molecule of NAD from NADH and thus facilitating oxidation of ethanol. The fact
that acetoacetate was not detectable in liver spectra suggests that this molecule is
transported into the blood. Since both a single dose of ethanol and the 4-day-binge
treatment caused a similar increase in beta-hydroxybutyrate, induction of enzymes does
not appear to play a role in ethanol-induced ketone body formation.
3.4.2 Energy Metabolites in Brain
Brain tissue is extremely sensitive to ischemia and hypoxia, and despite our efforts to
freeze brain samples rapidly, spectra reveal high lactate levels and low glucose levels
(Fig 3.8) indicative of anaerobic metabolism during the interval between decapitation
and complete freezing of brain tissue. Though this anaerobic interval undoubtedly
perturbed levels of energy metabolites such as glucose, ATP, and phosphocreatine,
it has been shown not to alter brain amino acid levels (Siesjo, 1978), and the spectra
reveal numerous well-resolved signals from various brain metabolites that are within the
ranges measured in previous studies (Govindaraju et al., 2000). Thus we felt confident
that with the exception of glucose, lactate, and other energy metabolites, the values we
measured were reasonable estimates of the in vivo concentrations for brain metabolites,
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and that therefore metabolomic analysis of these samples was appropriate.
3.4.3 Betaine Metabolism and Transmethylation
Previous studies have found that betaine, an important precursor of s-adenosylmethionine
(SAM), is decreased by chronic ethanol administration in rats due to increased activity
of betaine-homocysteine S-methyltransferase (EC 2.1.1.5) (Barak et al., 1996). More-
over, dietary supplementation with betaine during chronic ethanol feeding prevents the
formation of fatty liver (Barak et al., 1993). It is possible that in control animals, BHT
treatment increases betaine levels by providing an alternative donor for methyl groups,
but it appears that during binge ethanol exposure, BHT does not prevent a decrease
in hepatic betaine (Fig. 3.7). To our knowledge, this is the first finding of decreased
hepatic betaine after only 4 days of ethanol intake. Presumably this decrease signifies
increased utilization of betaine for the production of SAM, which may be related to
the methylation of DNA associated with ethanol exposure (Bleich et al., 2006).
3.4.4 Brain Metabolites
As discussed above, the tissue collection procedure introduced ischemic changes in the
brain energy metabolites but should not have altered brain amino acids (Siesjo, 1978).
Given the large number of well-resolved peaks from a large number of molecules in the
brain spectra, it would seem an ideal data set for metabolomic analysis. The relative
lack of effect of ethanol on endogenous brain metabolites is somewhat surprising, but
one must keep in mind that ethanol’s well-documented effects on the release of various
amino acids in brain will not be detected in whole-brain extracts. The only effects that
we can observe in this study are those that change the whole-brain concentration of
a given molecule: net synthesis, catabolism, or transport. Previous studies using in
vivo proton NMR spectroscopy (MRS) after a single dose of ethanol failed to detect
changes in endogenous brain metabolites in rhesus monkeys (Kaufman et al., 1994),
and humans (Mendelson et al., 1990). Following 16 weeks of ethanol treatment in rats,
phosphocholine increased 1.2-fold, and after 60 weeks, glycerophosphocholine decreased
1.5-fold (Lee et al., 2003), suggesting that the effect of chronic ethanol exposure varies
over time. Other investigators found a 1.25-fold decrease in the mIns/(Cr+PCr) ratio
after 8 weeks of ethanol treatment in rats (Braunova et al., 2000). Perhaps a more
pertinent measure than the effect of ethanol on concentrations of brain metabolites is
the effect of ethanol on various fluxes of metabolites in brain. Brain metabolism is
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known to be compartmentalized in astrocytes and neurons, with separate TCA cycles
operating in each compartment (Benjamin and Quastel, 1972). Acetate is a substrate
for the astrocytic compartment (Waniewski and Martin, 1998), and during chronic
ethanol exposure it may disrupt the normal metabolic coupling between neurons and
astrocytes required for neurotransmission (Sibson et al., 1998). Studies are currently
underway to address this point.
3.4.5 Ethyl Glucuronide
Previous studies have found that high concentrations of ethanol cause formation of EtG
in the liver. Reports have focused on determination of ethyl glucuronide using sensitive
techniques such as ELISA and GC-MS to achieve low detection thresholds. However,
quantification via NMR has not been demonstrated to date. The fact that hepatic EtG
reached near-maximal levels (2mmol/kg) within 3 hours of ethanol consumption (Fig.
3.5) while the time constant for elimination is on the order of days (Wurst et al., 2004),
suggests a significant barrier to the release of EtG from the liver into the blood. Our
studies suggest that EtG is elevated by the first dose of ethanol and remains elevated
for days during ethanol treatment.
Interestingly, BHT reduced the formation of EtG. The simplest explanation for the
decreased formation of EtG in binge-ethanol animals pretreated with BHT is that the
BHT (35% of which is eliminated via glucuronidation (Lanigan and Yamarik, 2002))
was a better substrate for activated glucuronide than was ethanol. Our reasoning is
as follows: if a large (80mM BEC) dose of ethanol is required to produce EtG, but
even at that concentration, only 0.1% is metabolized via glucuronidation, whereas 35%
of a much smaller dose of BHT is glucuronidated, then BHT is at least 350 times
more likely to react with activated glucuronide than is ethanol. On the other hand,
the daily dose of BHT (120mg/kg) is, on a molar basis, 1/320 the size of the daily
ethanol dose. Therefore, in terms of the probability of reacting to form a glucuronide,
a 120mg/kg dose of BHT and an 8.6g/kg dose of ethanol might reasonably be expected
to compete on an equal basis for activated glucuronide. On the other hand, our data
do not allow us to exclude the possibilities that (i) BHT enhanced release of EtG from
liver without altering formation, or (ii) that BHT decreased EtG formation via a more
complex mechanism than the one described above. Further studies will be required to
clarify this point. In any case, to our knowledge, this is the first report of a compound
that could be consumed as part of a normal diet that can decrease the formation of
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EtG. If our interpretation is correct, one would anticipate an even greater inhibition of
EtG formation in humans who excrete almost twice as much (63%) of a dose of BHT
as glucuronide conjugates, compared to rats (Lanigan and Yamarik, 2002). This effect
has important implications for the use of EtG as a biomarker for ethanol use since the
formation of EtG can be reduced by recent consumption of BHT, and, presumably,
many other compounds that are eliminated via glucuronidation would exert a similar
effect. While this phenomenon would not produce false-positive results, it may diminish
the value of negative EtG test results in ruling out recent ethanol use (Wurst et al.,
2000; Skipper et al., 2004; Droenner et al., 2002). Additional studies, particularly in
humans, will be required to clarify this issue.
3.4.6 PC Analysis
PC analysis provided an unbiased assessment of the spectral changes induced by ethanol
in each of the tissues studied. Given the small sample size relative to the number
of spectral regions analyzed, the clustering of the 7 treatment groups in Figure 3.9
indicates that significant and consistent perturbations of the endogenous metabolites
were present in each treatment condition. Moreover, when the samples from the 4-
day binge treatment were analyzed separately, the ethanol-treated samples could be
classified with 100% accuracy using a linear separation in the scores plot (Fig. 3.10a).
The same is true of the serum samples (Fig. 3.11a). While clustering of the brain data
was less impressive, it appears that certain metabolites with large amplitude in PC2
may be altered by ethanol. The limited sample size in this study precludes any definite
conclusion on this point. A larger study, perhaps including binge-ethanol-treated brain
samples would have a greater chance of identifying metabolites that are altered in brain.
In addition, though previous studies indicate that rapid freezing after decapitation does
not substantially alter brain amino acids (Siesjo, 1978), it might be the case that certain
biochemical differences due to ethanol are lost during the sacrifice and tissue collection
procedure. Microwave irradiation, funnel-freeze, or freeze-blow techniques to collect
brain tissue might reveal differences that cannot be detected with the techniques and
equipment used in this study.
3.4.7 Conclusion
Using NMR-based metabolomics we have identified key metabolic effects of both acute
and 4-day binge ethanol exposure. By determining that ethanol decreased lactate and
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alanine in both the liver and blood, we were able to focus on key differences between
isolated perfusion studies and the conditions that prevail in vivo. This metabolomic
analysis led to the insight that the depletion of hepatic alanine in vivo could produce
a futile cycle that would not be discovered during the perfusion of isolated livers, and
thus led us to propose a model that resolves apparently discordant findings regarding
the effect of ethanol on gluconeogenesis.
In addition, the use of NMR spectroscopy removed potential confounding issues
associated with chemical assays used to measure serum lactate in an older study. We
were therefore able to show that a single dose of ethanol actually decreases serum
lactate contrary to previous reports.
Finally, although PC analysis provides a useful tool for identification of metabolites
perturbed by exogenous toxins, we note that detailed spectral analysis is required to
understand the biochemical information at the mechanistic level. Of critical importance
is correct assignment of spectral signals to the metabolites that produce them. Towards
this end we have clarified the identity of betaine in liver extracts in this report, and
identified ethyl glucuronide in a separate report (chapter 2). The identification of these
metabolites in our spectra enabled us to extract information latent in our metabolomic
data, and thus to report for the first time that 4-day binge ethanol administration de-
creases hepatic betaine, and that BHT reduces hepatic EtG levels during binge ethanol
administration.
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Chapter 4
Cerebral Metabolism of
Ethanol-Derived Acetate: A
Metabolic Basis for Dependence?
4.1 Introduction
Ethanol is consumed in alcoholic beverages in large quantities that contribute nutri-
tional calories and cause a major alteration in metabolism. Ethanol is perhaps the only
drug that produces millimolar blood levels of its direct metabolite, acetate, which can
be a source of energy. Ethanol oxidation in the liver accounts for more than 90% of
ethanol elimination (Norberg et al., 2003), producing the two-carbon fatty acid, ac-
etate, much of which is not metabolized in liver. Nearly all of the acetate produced
during hepatic ethanol oxidation is released into the blood (Jucker et al., 1998). Ac-
etate can enter the TCA cycle to be metabolized. However, it needs to be converted
to acetyl-CoA by Acetyl-CoA Synthetase (ACoAS, EC 6.2.1.1) which may regulate the
level of acetate metabolism by cells. Thus, the metabolic effects of ethanol involve pri-
marily ethanol metabolism in liver and subsequent metabolism of acetate in multiple
other tissues.
Acetate metabolism might be important in tissues with high metabolic activity and
blood flow such as the brain. In fact, it has been hypothesized that brain acetate
metabolism may increase during chronic ethanol consumption, perhaps contributing to
neuroadaptation and dependence to ethanol (Roach and Resse, 1972; Derr et al., 1981;
Israel et al., 1994; Volkow et al., 2006). The rationale for this hypothesis is based on the
following findings. Acetate is produced at low levels by intestinal flora (Waniewski and
Martin, 1998), leading to a basal blood acetate concentration of approximately 0.1-0.3
mM in humans (Sarkola et al., 2002), and rats (Carmichael et al., 1991). During hepatic
oxidation of ethanol, more than 90% of the resulting acetate is released into the blood
(Jucker et al., 1998), causing the blood acetate concentration to rise 3- to 7-fold to the
1-2mM range (Carmichael et al., 1991; Sarkola et al., 2002). The zero-order kinetics
of ethanol elimination imply a constant rate of acetate production for nearly the entire
duration of ethanol metabolism. Thus, blood acetate is maintained at a significantly
elevated levels throughout the period of ethanol intoxication (Orrego et al., 1988). In
alcoholics and heavy drinkers, the rate of ethanol metabolism is more rapid, resulting in
acetate plateau levels approximately 2-fold higher in alcohol-tolerant individuals than
in controls (Korri et al., 1985), suggesting greater availability of acetate as a substrate
for brain metabolism. Therefore, ethanol metabolism results in an abundant supply of
acetate in the blood that could alter brain metabolism.
Early studies using [14C] acetate demonstrated that carbons from acetate show rapid
metabolism in brain and preferential incorporation into cerebral glutamine rather than
glutamate, while the reverse occurred when [14C] glucose was provided as the tracer
molecule (O’Neal and Koeppe, 1966). These observations gave rise to the hypothesis
that cerebral metabolism consists of two compartments: one that preferentially me-
tabolizes acetate and contains a ”small” glutamate pool which is rapidly converted to
glutamine, and a second compartment that utilizes glucose and contains a ”large” glu-
tamate pool (Van den Berg et al., 1969). Since astrocytes express glutamine synthetase
(Norenberg and Martinez-Hernandez, 1979), it was supposed that they represent the
”small” glutamate pool, and that cerebral acetate metabolism takes place mainly within
astrocytes (See Fig. 4.1). This view is now widely accepted (Zwingmann and Leibfritz,
2003), and an acetate transporter that is absent on neurons appears to account for the
selectivity of acetate in labelling the astrocytic compartment (Waniewski and Martin,
1998). Whereas many studies used exogenous acetate as a tracer, Roach et al. showed
that [14C] ethanol given intraperitoneally to hamsters labeled brain glutamine, gluta-
mate, and GABA (Roach and Resse, 1972), supporting the idea that acetate derived
from ethanol oxidation is a substrate for the brain. These findings suggest that ethanol
derived plasma acetate is metabolized by brain astrocytes providing an energy source
that differs from that provided by glucose.
Recently, Volkow et al. used PET studies in human volunteers to show that modest
doses of ethanol reduce the rate of brain glucose utilization by 10-23% (Volkow et al.,
2006). These decrements in glucose utilization are out of proportion to the sedative
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Figure 4.1: Model for cerebral metabolism of [2-13C] acetate showing incorporation of
13C into the astrocytic TCA cycle and the resulting effect on the glutamine-glutamate
cycle. Acetate is transported into astrocytes, converted into Acetyl-CoA by ACoAS,
and enters the TCA cycle. After the first quarter turn, labeled carbon skeletons can
leave the TCA cycle as glutamate, which is rapidly converted to glutamine in astro-
cytes. Both glutamine and glutamate will be labeled at the 4-carbon (closed circles)
from this first turn labeling. Astrocytic glutamine is transported to neurons as a pre-
cursor for neurotransmitter glutamate. Glutamate released from neurons is taken up
by astrocytes, thus completing the glutamine-glutamate cycle. Carbons which traverse
a complete turn of the TCA cycle are scrambled due to the molecular symmetry of
succinate, and thus glutamate and glutamine C3 and C2 are labeled equally on the
second turn (open circles). GABA derived from glutamate labeled in C2 and C3 will
be labeled in C3 and C4. Abbreviations: a-Ketoglutarate, a-KG; Oxaloacetate, OAA,
Succinate, Succ, Glutamate, Glu, Glutamine, Gln, γ-aminobutyric acid, GABA; Glu-
tamine Synthetase, GS.
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effect of ethanol, suggesting that ethanol does not decrease brain metabolic demand
at these doses. Therefore, this finding could indicate a shift in substrate utilization
from glucose to acetate during ethanol consumption, even at low doses of ethanol. The
same group found that larger doses of ethanol (1g/kg) caused similar reductions in
brain metabolism of glucose, with greater reductions in alcoholics than control subjects
(Volkow et al., 1990), suggesting that alcohol exposure may result in increased brain
utilization of acetate. Likewise, decreased glucose metabolism in brain during ethanol
exposure occurs in rats (Learn et al., 2003) and hamsters (Roach and Reese, 1971),
demonstrating that rodents are suitable model organisms for the study of this phe-
nomenon. Taken together, these data support the hypothesis that brain may adapt to
chronic ethanol intake by increasing brain metabolism of acetate. One putative mech-
anism could involve greater capacity to transport acetate into astrocytes and greater
activity of ACoAS, an enzyme required to bring acetate into the TCA cycle to form
glutamine-glutamate. Kiselevski et al. found a 36% increase in cortical ACoAS ac-
tivity in homogenates of rat cortex following 7 days of ethanol treatment (Kiselevski
et al., 2003), consistent with an adaptive increase in acetate metabolism by brain during
chronic ethanol exposure.
Neurons and glia are metabolically linked. Neurons rely on astrocytes for metabolic
support, including supply of precursors for synthesis of glutamate. Inhibition of the
astrocytic TCA cycle by fluoroacetate in day-old chicks inhibits glutamate-dependent
aversive learning, but injection of glutamate overcomes this effect (Hertz et al., 1996).
If astrocytes fail to support neuronal synthesis of glutamate required for aversive learn-
ing, this could contribute to perseverative behavior observed after withdrawal (Obernier
et al., 2002b) that interferes with recovery. In addition, recent evidence implicates as-
trocytes as active participants in synaptic events, capable of releasing glutamate in
a Ca2+ -dependent fashion (Newman, 2003). Derr et al. (Derr et al., 1981) found
that intragastric (i.g.) injections of sodium acetate significantly reduce the incidence of
whole body tremors in ethanol withdrawing physically dependent rats (Majchrowicz,
1975). This result is consistent with acetate becoming a component of the development
of ethanol dependence, perhaps by alterations in brain use of acetate. To investigate
ethanol-acetate metabolism in brain after acute and chronic ethanol treatment we de-
signed experiments using 13C-labeled tracers. Our objectives were to determine con-
clusively whether ethanol-derived acetate is a substrate for brain metabolism, and also
to determine whether chronic ethanol exposure would induce an increase in cerebral
acetate metabolism. To our knowledge, ours are the first studies of brain metabolism
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after administration of 13C ethanol. The 13C NMR studies we report offer an impor-
tant advantage over previous 14C studies (Mushahwar and Koeppe, 1972; Roach and
Resse, 1972) because 13C NMR spectra inherently contain positional information about
the particular carbon atoms within a given metabolite that are labeled by the tracer.
This additional level of detail enables the differentiation of carbon isotopomers, and
thereby reveals the metabolic history of the labeled carbon skeletons. Thus, 13C iso-
topomer analysis strengthens any conclusions about which labeled substrates derived
from ethanol, if any, are metabolized in the brain. Finally, we collected serum samples
from all animals at the time of sacrifice to determine which labeled substrates were
available in blood as substrates for brain metabolism.
4.2 Methods
4.2.1 Chemicals
[2-13C] acetate, [2-13C] ethanol, and 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid (TSP)
(all 99% enriched) were obtained from Isotec (Miamisburg, OH). All other chemicals
were of the highest purity available.
4.2.2 Animal Procedures
All procedures for handling and sacrifice of animals were approved by the UNC-Chapel
Hill Internal Animal Care and Use Committee (IACUC) and were in accordance with
National Institute of Health regulation for the care and use of animals in research.
Adult male Sprague-Dawley rats (Charles River Labs, Inc.) were allowed to acclimate
for 2-4 days prior to the start of all experiments. One group of animals was fasted
overnight and given a single dose of either [2-13C] ethanol (1g/kg, i.g.), [2-13C] acetate
(0.5g/kg i.p.), or natural abundance ethanol (1g/kg, i.g.). Animals were sacrificed at 30
minutes (acetate) or 15, 30, 60, and 240 minutes (ethanol) after being dosed (see Fig.
4.2, ”Acute group” ). Time points were selected on the basis of previous studies using
13C acetate in rats (Hassel et al., 1995). The dose of [2-13C] acetate was selected on
the basis of the same studies, and the dose of [2-13C] ethanol was selected on the basis
that 1g/kg of ethanol produces near maximal serum acetate levels (Carmichael et al.,
1991). Five minutes prior to sacrifice, animals were anesthetized with pentobarbital
sodium (0.65ml of a 50mg/ml solution in water, i.p.). Following the onset of surgical
anesthesia, an abdominal incision exposed the liver and inferior vena cava (IVC). A
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Figure 4.2: Experimental Design. Three treatment groups were studied: (i) acutely
dosed, ethanol-naive animals, (ii) animals dosed for 10 days with natural abundance
ethanol (5g/kg/day, i.g. of 20ethanol w/v in water), and (iii) control animals dosed
for 10 days with water (i.g.). Animals from each group were selected randomly for
dosing (up arrows) with 13C-enriched ethanol, or acetate, or natural abundance ethanol.
Animals were sacrificed (down arrows) and tissues were collected (as described in the
text) at the time points indicated.
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blood sample (2-4ml) was collected from the IVC and allowed to clot on ice. Next,
each animal was decapitated and the skull immediately immersed in liquid nitrogen
with agitation in the liquid to hasten the freezing process, while a small piece of liver
(1-2g) was quickly removed, wrapped in aluminum foil, and frozen in liquid nitrogen.
The time from surgical anesthesia to decapitation was approximately 90 seconds; the
time between the start of blood withdrawal and decapitation was less than 45 seconds;
the time from decapitation to placing the liver sample in liquid nitrogen was less than
30 seconds. Clotted blood was centrifuged, and serum was removed and stored, along
with liver and skull samples, at -80◦C until further analysis.
A second group of animals received either ethanol (5g/kg, 20% w/v, i.g.) or water
(i.g.) daily for 10 days. During this time animals had free access to food and water,
and were monitored for signs of distress. Following the 10-day treatment with either
ethanol or water, animals were fasted overnight, and on the 11th day they were dosed
with either [2-13C] ethanol (1g/kg, i.g.) or [2-13C] acetate (0.5g/kg i.p.) and sacrificed
as described above (see Fig. 1). Two animals were excluded from analysis, one due to
incomplete ethanol dosing and one due to loss of tissue homogenate during processing.
4.2.3 Tissue extraction
Brains were removed from skulls under liquid nitrogen using a rotary cutting tool
(Dremel) and a hammer and chisel. Frozen brains were pulverized under liquid nitrogen
in a stainless steel mortar and pestle and extracted twice with ice cold 8% perchloric
acid (Gutmann and Wahlefeld, 1974). The pooled extracts were neutralized with 5M
K2CO3, insoluble potassium perchlorate salts were removed by centrifugation at 0◦C,
and the extracts were lyophilized to a dry white powder (Fan et al., 1986).
4.2.4 NMR and HPLC sample preparation
Lyophilized extracts were dissolved in 2ml/g tissue of D2O (99.9%, Cambridge Isotope
Laboratories, Andover, MA) containing 0.1M phosphate buffer at pH 7.0 (pD 6.6), 0.1%
1-4 dioxane (Fisher Chemicals, Fair Lawn, NJ) as a 13C chemical shift and concentration
reference (Kanamatsu and Tsukada, 1999), 14.4mM sodium formate (Alfa Aesar, Ward
Hill, MA) as a proton concentration reference (Kriat et al., 1992), and TSP as a proton
chemical shift reference. Sample pH (uncorrected) was adjusted to 6.90-7.10 using DCl
and NaOD, and the sample was centrifuged to sediment insoluble perchlorate salts. 700
L was withdrawn for NMR analysis, 100 L was diluted 7.5-fold with HPLC-grade water
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for HPLC analysis, and this was frozen alongside the remainder of the NMR sample at
-80◦C.
Serum samples were prepared by thawing from -80◦C in a microcentrifuge at 13000
rpm for 4 minutes, after which 500µL of serum was mixed with 250µL of a stock
solution containing 14.4mM sodium formate and 1.6mM TSP in 99.9% D2O. 700µL of
the resulting mixture was transferred to a 5mm NMR tube for analysis.
4.2.5 NMR spectroscopy
Prior to 13C NMR spectroscopy of brain extracts, proton spectra were acquired on a
Varian Inova 400MHz spectrometer equipped with a 5mm broad band probe, using the
following parameters: duty cycle 45s, flip angle 90◦ , 2 s weak irradiation of residual
water protons, 32k points, 4200 Hz spectral width. Next, proton-decoupled 100.54 MHz
13C NMR spectra of brain extracts were acquired on the same instrument, with the
inner coil of the probe tuned to 13C. The spectra were accumulated in 4096 transients,
using a 45◦ flip angle, 25kHz spectral width, 64k data points, and a duty cycle of 8 sec-
onds. Some samples were acquired with WALTZ proton decoupling during acquisition
while others were acquired with continuous GARP decoupling. Appropriate saturation
factors were computed for each acquisition method. Proton spectra of serum samples
were acquired on a 700MHz Varian Inova spectrometer with a cold probe using the
following parameters: duty cycle 45 s, 8 repetitions, 2 s weak irradiation of residual
water protons, 32k points, 12 kHz spectral width.
All spectra were acquired with oversampling to increase the effective dynamic range.
4.2.6 NMR spectral processing
All NMR data processing was accomplished using software written in-house for this
purpose in the Matlab environment (The MathWorks, Inc., Natick, MA), and validated
by processing selected spectra in alternative commercial (ACD) and non-commercial
packages. The first 3 points of each FID were calculated using linear back prediction
(basis = points 4-516, 32 coefficients) in order to remove pulse breakthrough. FIDs were
zeropadded by a factor of 2, and 13C FIDs were apodized with an exponential function
corresponding to 5Hz lorentzian broadening prior to fourier transformation. Spectra
were phase corrected, and integrals of the real spectrum were used for quantification of
proton spectra. Peak heights were judged to be more reliable quantitative measures in
the 13C NMR data (Garcia-Espinosa et al., 2003).
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4.2.7 HPLC analysis
HPLC analysis was accomplished using precolumn derivitization with 6-aminoquinolyl-
N hydroxysuccinimidyl carbamate (AQC) (Cohen and Michaud, 1993), separation on a
C18 reverse phase column (5µm, 4.6 × 250 mm Agilent Zorbax SB-C18) with gradient
elution (solvent A: acetonitrile, solvent B: ammonium acetate, pH 4.9), and fluores-
cence detection (λex = 245nm, λem = 395nm). Small injection volumes (10µL ) were
important to maintain good separation of the early-eluting peaks (Liu et al., 1998).
4.2.8 Calculation of Fractional Enrichment from 13C NMR
data
Saturation factors for each carbon resonance due to T1 relaxation and NOE effects
were computed as described previously (Cohen, 1983; Brainard et al., 1989). Briefly,
after acquiring data on control samples from animals that received natural abundance
ethanol, additional pure (natural abundance) compounds were added to the NMR
sample to raise the concentration to the 10-30mM range, 20µL was withdrawn and
diluted for HPLC analysis, and 1H-decoupled- 13C spectra were re-acquired. Saturation
factors were computed based on the ratio
SFxn =
[xn]apparent
[x]actual
, (4.1)
where SFxn is the saturation factor for the resonance of carbon n in molecule x,
[xn]apparent is the apparent concentration of xn based on the ratio of its NMR intensity
to that of the dioxane concentration reference, and [x]actual is the actual concentration
of x measured by HPLC. For animals that received 13C tracers, absolute concentra-
tion of 13C in each carbon of each molecule was estimated by the ratio of the peak
intensity for each resonance to that of the natural abundance of the 4 dioxane carbons,
divided by the saturation factor calculated above. Fractional enrichment (FE) above
natural abundance for each carbon atom in each molecule was calculated as described
in (Badar-Goffer et al., 1990):
FExn =
([xn]− 0.01108 ∗ [x])
[x]
, (4.2)
where FExn is the fractional enrichment of carbon n in molecule x, [x] is the concen-
tration of molecule x measured by HPLC, and 0.01108 reflects the the ∼ 1.1% natural
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abundance of 13C.
4.2.9 Calculation of Fractional Enrichment from 1HNMR data
In regions of the proton spectra where a metabolite signal and its 13C satellite peaks
were well-resolved (e.g. the signals from methyl protons of acetate and lactate, and
the α-anomeric proton of glucose), 13C fractional enrichment was estimated (Cerdan
et al., 1990). By comparing proton spectra of each sample with and without 13C-
decoupling during acquisition, we verified that suspected 13C satellite peaks in the
proton spectrum were in fact due to 13C-1H coupling due to enrichment of 13C. The
lower bound for fractional enrichment measurement using this method was determined
by computing the signal-to-noise ratio (SNR) (based on the peak-to-peak noise) for the
protons attached to the carbon in question, and assuming that a signal-to-noise ratio
(SNR) greater than 3 was required for unequivocal detection of 13C satellites. The
minimum fractional enrichment that would give SNR>3 for 13C satellite peaks is
FEmin =
(3 + 3)
(SNR + 3 + 3)
=
6
SNR + 6
. (4.3)
4.2.10 Model of Cerebral Metabolism and analysis
To interpret the labeling of cerebral amino acids from ethanol-derived acetate, we used
the accepted two-compartment model of cerebral metabolism in which neuronal and
glial TCA cycles operate independently (Fig. 2) (Haberg et al., 1998). The metabolism
of [2-13C] acetate by astrocytes results in first-turn labeling of glutamate C4, which is
rapidly converted to glutamine by the action of glutamine synthase. The operation
of the glutamate-glutamine cycle moves glutamine to neurons where it is converted to
glutamate, released during neurotransmission, and taken up into astrocytes where it
is converted back to glutamine. In GABAergic neurons, GABA can be synthesized
either from glutamate carbon skeletons derived directly from astrocytic glutamine, or
from the pool of neuronal glutamate that has traversed the neuronal TCA cycle (Hassel
et al., 1995). We used the approach described by Hassel et al. to estimate the fractional
loss of labeled intermediates from the TCA cycle on each turn via the C3/C4 ratio in
glutamate and glutamine, and the corresponding C3/C2 ratio in GABA (Hassel et al.,
1995).
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4.2.11 Statistical analysis
The statistical significance of differences between means of measured parameters in dif-
ferent treatment groups was assessed using a t-test (2-tailed, unequal variance). When
multiple comparisons were made, Bonferroni correction was applied. When comparing
the FE of carbons predicted by our model to have identical enrichment, data for each
animal were analyzed using a paired t-test (2-tailed).
4.3 Results & Discussion
4.3.1 Animals and tissue extraction
Acute treatment resulted in maximal blood levels of ∼ 20mM (Table 1) at 30 min
after dosing. Animals dosed with ethanol for 10 days prior to dosing with labeled
ethanol reached maximal blood levels of ∼15mM at 60 minutes after dosing (Table 1).
It is likely that increased first-pass metabolism of ethanol contributed to the lower and
delayed peak ethanol levels in the 10-day ethanol group.
During the 10-day treatment with ethanol, animals were observed to show mild
tremors during handling starting on day 6, but no seizures were observed. During the
10 day treatment, animals in both the ethanol and water groups gained weight. Ethanol
is known to have wasted calories and to reduce weight gain. For comparison, group
weights were, acute: 277±9.2g (n=26), 10-day-ethanol: 323±20.8g (n=22), and 10-day-
water: 343± 23.2 (n=8). The trend towards lower weight in the ethanol-treated group
versus the 10-day-water group did not reach statistical significance. There was, however,
a significant difference between the pooled weights of all 10-day animals (ethanol- and
water-treated): (328±22.9g, n=30) versus the acute group (p<1013, two tailed t-test,
unequal variance). Differences were also significant (p<0.0001) when comparing either
the 10-day-water or 10-day-ethanol group to the acute group. In summary, both groups
of 10-day animals gained weight (1.2-fold, on average) compared to the acute group.
4.3.2 Serum: availability of 13C-acetate for brain metabolism
Analysis of 700MHz proton spectra of serum (Fig. 4.3) collected at sacrifice enabled us
to determine concentrations and fractional enrichments of various potential substrates
for brain metabolism in each group (Table 1). By 15 min after dosing with [2-13C]
ethanol, acutely-treated animals reached serum acetate levels of 0.67mM at 80% frac-
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Figure 4.3: 700MHz proton spectra of serum. 15 minutes after dosing with with [2-13C]
ethanol, both acutely dosed (a) and 10-day-ethanol-treated (b) animals show substan-
tial (>2/3) fractional enrichment of serum acetate, indicating that [2-13C] ethanol is
rapidly metabolized to [2-13C] acetate in the liver and quickly released into the blood.
The quick rise in [2-13C] acetate indicates that abundant ethanol-derived acetate was
available as a substrate for brain metabolism within minutes of ethanol ingestion. By
240 minutes after dosing with [2-13C] ethanol, both nave (c) and 10-day-ethanol-treated
(d) animals eliminated almost all ethanol. The fractional enrichment of acetate de-
creased substantially versus 15 minutes post-dose, due to the exhaustion of the supply
of [2-13C] ethanol. However, 13C-satellite peaks are visible for lactate, indicating that
13C label has traversed the hepatic TCA cycle and entered lactate and glucose (see Fig.
4). By comparing spectra collected with and without 13C-decoupling, we were able to
verify that suspected 13C satellite peaks were in fact due to 13C coupling (see Fig. 4).
The only molecules that had appreciable 13C labeling in the 700MHz proton spectra of
serum were ethanol, acetate, lactate, and glucose. By virtue of the high signal to noise
of spectra collected using the 700MHz spectrometer with the cold probe, we were able
to measure fractional enrichment as low as 1(see Fig 4). Assignments: 1 t, half ethanol
2-13CH3; 2 d, beta-hydroxybutyrate-CH3; 3 t, half ethanol 2-
13CH3; 4 d, lactate 3-CH3;
5 d, alanine 3-CH3; 6 s, half acetate 2-
13CH3; 7 s, acetate 2-12CH3; 8 s, half acetate
2-13CH3; 9 q, ethanol 1-CH2; 10 q, lactate 2-CH; 11 d, beta-glucose 1-CH; 12 residual
water protons; 13 d, alpha-glucose 1-CH; 14 d, half lactate 3-13CH3; 15 d, half lactate
3-13CH3; Abbreviations: d, doublet; q, quartet; s, singlet; t, triplet;
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Table 4.1: Serum Concentrations and Enrichments After Dosing with [2-13C] Ethanol
or Acetate.
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tional enrichment (Fig. 4.3a, Table 3). Ethanol concentration peaked at 30 minutes
after dosing at ∼ 20mM. The acetate concentration continued to rise to 0.75mM at 60
min, and acetate fractional enrichment remained approximately 80% during this time.
The elevated serum acetate concentration during ethanol metabolism together with the
high fractional enrichment, confirm the availability of ethanol-derived acetate (Jucker
et al., 1998) as substrate for brain metabolism within minutes of ethanol ingestion.
For the chronic ethanol group dosed with [2-13C] ethanol, serum acetate reached 0.95
mM 15 minutes after dosing, significantly higher than in the acutely-treated group. As
with the acutely-treated group, serum acetate remained elevated with FE ∼ 80% for
the first hour. In this group, ethanol peaked 60 minutes after dosing at ∼ 15mM;
the delayed peak and lower blood ethanol in the chronic group (Table 1) are most
likely the result of increased first-pass ethanol metabolism (Eckardt et al., 1998). We
anticipated that our 10-day ethanol treatment would produce even greater increases in
acetate production, analogous to the finding of ∼2-fold greater acetate levels in human
alcoholics during intoxication (Korri et al., 1985). However, it is possible that either
this treatment was insufficient to produce such dramatic increases, or that a larger dose
of ethanol would be required to demonstrate the changes.
Acutely-treated animals injected intraperitoneally with [2-13C] acetate achieved sig-
nificantly higher blood acetate levels (mean 4.26mM, range 3.41 to 5.92mM, n=4) than
animals treated with [2-13C] ethanol (see Table 1). Curiously, animals injected with [2-
13C] acetate after 10 days of either water or ethanol treatment showed significantly lower
serum acetate concentrations (mean 1.07mM, range 0.53 to 2.13, n=8) than acutely-
treated animals (Table 1). The lower serum acetate in the 10-day animals is somewhat
puzzling, but since the control (water-treated) group exhibited the same trend as the
ethanol treated group, we speculate that altered pharmacokinetics in the 10-day groups
(which weighed on average 24% more than the acutely-treated group) may have been
responsible. Increased abdominal fat and relatively larger volume of distribution may
have contributed to lower serum acetate levels in the larger animals.
4.3.3 Serum: assessment of 13C-labeling in molecules other
than acetate
Though 90% of the acetate produced during hepatic metabolism of [2-13C] ethanol is
released into the serum (Jucker et al., 1998), the remaining 10% may enter the TCA
cycle and label other molecules with 13C. On the first turn of the TCA cycle, glutamate
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Figure 4.4: Confirming the identification of glucose 13C satellite peaks in 700MHz
proton spectra. Panel (a) represents an expanded view of the spectrum shown in Fig.
3c (serum 240 minutes after dosing with [2-13C] ethanol in a nave animal), collected
without 13C-decoupling. In this spectrum, glucose and carbon satellites of glucose are
evident. In the 13C-decoupled 700MHz proton spectrum of the same sample (b), the
13C-satellites are no longer present. While the enrichment of the 1-carbon in glucose was
greater than natural abundance, even at 4 hours the FE was less than 5%, affirming the
expectation that [2-13C] acetate was the primary labeled substrate available for brain
metabolism in these experiments. Assignments: 1 d, half [2-13C] alpha-glucose 1-CH;
2 d, alpha-glucose 1-CH; 3 d, half [2-13C] alpha-glucose 1-CH;
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(and also glutamine) labeled in the C4 position could result (Fig. 2). Subsequently,
oxaloacetate labeled in the C2 or C3 position could continue through the second turn of
the TCA cycle to produce glutamate and glutamine labeled at the C2 or C3 position.
Alternatively, the labeled oxaloacetate could enter the gluconeogenic pathway, produc-
ing pyruvate labeled in the C2 or C3 position, which in turn could produce glucose
labeled with equal probability in C1, C2, C5 or C6, or lactate labeled in C2 or C3.
Thus, we measured the availability of these 13C-labeled molecules in serum by observ-
ing 13C-satellite peaks in our proton spectra. By comparing proton spectra collected
with and without 13C-decoupling, we verified that suspected 13C-satellite peaks were in
fact due to 13C-1H coupling (Fig. 4). No evidence of significant enrichment of serum
glutamine was detected (though glutamine is a poor substrate for brain metabolism at
physiologic concentrations (O’Neal and Koeppe, 1966)). Concentrations and fractional
enrichments for serum lactate and glucose are summarized in Table 1, and as expected,
FE in these molecules was less than 5% at all time points up to 60 min. In acutely-
treated animals, glucose fractional enrichment was not statistically greater than zero
until 240 min. In 10-day-ethanol-treated animals, glucose FE was statistically elevated
at 30 min, probably reflecting increased gluconeogenesis in these animals, though it
remained less than 5% even at 240 min. These findings support our decision to omit
from our model (Fig. 2) the influx of 13C label into brain from substrates other than
acetate.
In addition to entering metabolites via the TCA cycle, acetate can enter ketone
bodies without traversing the TCA cycle. Acetoacetate is formed (via acetoacetyl-
CoA) by condensation of two molecules of acetyl-CoA, and thus would be labeled in
C2 and/or C4, as would beta-hydroxybutyrate, both of which can serve as substrates
for cerebral metabolism. We measured both acetoacetate and beta-hydroxybutyrate in
serum, but there was no detectable 13C enrichment of C4 (FE<20%) in either molecule.
4.3.4 Brain Fractional Enrichment: Acetate and other poten-
tial substrates
Having established the availability in serum of 13C-labeled substrates for brain metabolism,
we examined 13C incorporation into brain (Fig. 5). Despite 80% fractional enrichment
of serum acetate in animals treated with [2-13C] ethanol, fractional enrichment in brain
acetate was substantially lower in these animals; in most cases it was below the detec-
tion threshold in our proton spectra. By contrast, acutely-treated animals treated with
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[2-13C] acetate showed 38% FE of brain acetate, and also a 1.57- to 2.19-fold increase in
brain acetate concentration versus acutely-treated animals treated with [2-13C] ethanol.
This was the same group of animals that achieved a serum acetate concentration of more
than 4mM, suggesting that serum acetate concentration is an important determinant
for acetate entry into brain, as would be expected based on the Km of 9.4mM for
the acetate transporter determined by Waniewski and Martin (Waniewski and Martin,
1998). We speculate that in animals with serum acetate in the 1mM range, labeled
acetate that entered the brain may have entered the astrocytic TCA cycle without
mixing with the free acetate pool, whereas higher serum acetate in the acutely-treated
[2-13C] acetate-treated group caused labeled acetate to enter the brain faster than the
astrocytic TCA cycle consumed it. For all other animals, the finding of low fractional
enrichment of brain acetate in the face of 80% FE of serum acetate, and clear evidence
of acetate metabolism by brain (see below) suggests that the pool of free acetate in
the brain is not in exchange with the pool of acetate that enters the astrocytic TCA
cycle. It is possible that a pool of free acetate exists within neurons. In addition, the
low fractional enrichment of brain acetate suggests that the metabolism of acetate by
the brain during ethanol metabolism is limited by transport of acetate into the brain
rather than by entry of acetate into acetyl-CoA and the astrocytic TCA cycle.
Fractional enrichment in brain lactate was less than 5% for all groups of animals
except the acutely-treated animals 240 min after dosing with [2-13C] ethanol, and in
these animals it was only 6.85%. Brain lactate concentration was significantly elevated
in 10-day ethanol animals versus acutely-treated animals at 60 and 240 min after dosing
with [2-13C] ethanol. These groups of animals showed a trend toward increased serum
lactate (Table 1), and though not statistically significant due to the large standard
deviation, it is likely that increased uptake of lactate from blood into brain (O’Neal
and Koeppe, 1966) accounted for some of the increase in brain lactate.
4.3.5 Fractional Enrichment of Brain Amino Acids
To determine the metabolic path of ethanol-acetate metabolism we examined proton-
decoupled 13C spectra of brain following administration of [2-13C] ethanol and [2-13C]
acetate (Fig. 6). As predicted by our model (Fig. 2), the most intense labeling
occurs in glutamate and glutamine C4, with significant labeling in C2 and C3 of these
molecules as well (see Table 3). Consistent with our proton spectra (Fig. 5), acetate
C2 was substantially enriched in brain only following i.p. injections of [2-13C] acetate
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Table 2: Concentration and FE of lactate and acetate in brain
Naïve
time
Treatment (min) n [ ] (mM) FE (%) [ ] (mM) FE (%)
[2-13C] E 15 3 5.48 ± 1.16 0.99  ± 1.47 0.63 ± 0.04 1.92  ± 3.20
[2-13C] E 30 3 4.58 ± 2.49 1.33 ± 2.60 0.88 ± 0.07 3.85  ± 2.97
[2-13C] E 60 4 4.99 ± 1.32 2.41 ± 2.72 0.88 ± 0.38 2.06 ± 0.44
[2-13C] E 240 4 4.91 ± 1.02 6.85 ± 4.00 0.71 ± 0.16 2.25 ± 1.85
[2-13C] A 30 4 5.22  ± 2.81 3.07 ± 1.41 1.38 ± 0.31 b 38.43 ± 9.61 a
10-day ethanol
time
Treatment (min) n [ ] (mM) FE (%) [ ] (mM) FE (%)
[2-13C] E 15 4 4.89 ± 0.66 0.08 ± 1.54 0.43 ± 0.11 10.34 ± 5.58
[2-13C] E 30 4 6.20  ± 1.56 2.32 ± 0.61 0.27 ± 0.05 13.04 ± 6.21
[2-13C] E 60 4 8.95 ± 0.62 c 1.28 ± 0.20 0.37 ± 0.16 4.64 ± 3.44
[2-13C] E 240 4 7.69 ± 0.43 c 3.21 ± 2.61 0.42 ± 0.08 0.87 ± 6.26
[2-13C] A 30 4 6.44 ± 1.85 1.93 ± 2.15 0.46 ± 0.08 e 11.59 ± 12.6
10-day water
time
Treatment (min) n [ ] (mM) FE (%) [ ] (mM) FE (%)
[2-13C] E 60 4 7.94 ± 2.01 d 0.86 ± 0.68 0.38 ± 0.18 8.17 ± 8.51
[2-13C] A 30 4 6.48 ± 2.78 2.18 ± 0.44 0.53 ± 0.18 e 8.31 ± 2.56
Abbreviations: E, ethanol; A, acetate, [], concentration; FE, fractional enrichment.
a: p<0.05 2-tailed t-test, unequal variance versus acetate FE for every other Naïve group, with 
Bonferoni correction.
b: p<0.005 2-tailed t-test, unequal variance versus [acetate] for all other Naïve animals
c: p<0.01 2-tailed t-test, unequal variance versus [Lactate] in corresponding Naïve groups
d: not significant by 2-tailed t-test, unequal variance versus [Lactate] in corresponding Naïve group
e: p<0.05 2-tailed t-test, unequal variance versus [acetate] in Naïve group, with Bonferoni correction
Lactate Acetate
Lactate Acetate
Lactate Acetate
Table 4.2: Concentration and FE of lactate and acetate in brain.
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Figure 4.5: 400MHz proton spectra of perchloric acid extracts of brain. 60 minutes after
dosing with with [2-13C] ethanol, both nave (a) and 10-day-ethanol-treated (b) animals
show relatively low fractional enrichment of brain acetate, as judged by the size of 13C
satellite peaks. On the other hand, positive control brain collected 30 minutes after
dosing nave animals with [2-13C] acetate (c) show appreciable fractional enrichment
of brain acetate. In these animals, the serum acetate concentration was 4.3 1.1mM,
approximately 6-fold higher than [2-13C] ethanol-treated animals in (a) and (b), and 4-
fold higher than in 10-day ethanol-treated animals given [2-13C] acetate (d). Given that
serum acetate fractional enrichment was approximately 80% in all animals, and that the
pattern of fractional enrichment in brain amino acids (Table 3) was consistent with entry
of acetate into the astrocytic TCA cycle, it appears that when serum acetate is in the
1mM range, acetate that enters the brain proceeds directly into the TCA cycle without
mixing with free acetate in the brain. Thus, the rate-limiting step for incorporation
of acetate carbons into brain amino acids during ethanol metabolism appears to be
entry of acetate into the brain rather than conversion to acetyl-CoA or entry into the
TCA cycle. Fractional enrichment of acetate C2 and lactate C3 were quantified by
observing 13C satellite peaks (Table 4.2). The detection threshold was approximately
6% for lactate, and 18-38% for acetate, depending on the concentration of acetate.
Assignments: 1 d, lactate 3-CH3; 2 d, alanine 3-CH3; 3 qui, GABA 2-CH2; 4 s, acetate
2-12CH3; 5 s, NAA N-C(O)-CH3; 6 m, Glutamine 2-CH2; 7 m, Glutamate 2-CH2; 8
dd, NAA 3-CH2; 9 dd, Aspartate 3-CH2; 10 s: Creatine + Phosphocreatine N-CH3; 11
singlets from Choline, Phosphorylcholine, Glycerophosphocholine, N(CH3)3; 12 triplets
from taurine 2-CH2 and myo-inositol 5-CH; 13 t, taurine 1-CH2; 14 s, dioxane; 15 s:
Creatine + Phosphocreatine 2-CH2; 16 t, myo-inositol 2-CH; 17 q, lactate 2-CH; 18 dd,
NAA 2-CH; 19 residual water protons; 20 half [2-13C] acetate 2-13CH3; Abbreviations:
d, doublet; dd, doublet of doublets; m, multiplet; q, quartet; qui, quintet; s, singlet; t,
triplet; NAA N-acetyl aspartate.
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Figure 4.6: 100MHz proton-decoupled 13C spectra of perchloric acid extracts of brain.
Negative control spectrum (a) collected 120 minutes after dosing with natural abun-
dance ethanol shows smaller 13C signals than spectra from animals dosed with [2-13C].
Spectra from brain 60 minutes after dosing with [2-13C] ethanol in nave (b) and 10-day-
ethanol-treated (c) animals show similar patterns of enrichment in brain metabolites.
Positive control spectrum (d) from brain 30 minutes after dosing [2-13C] acetate shows
relatively selective labeling of glutamine-C4 and glutamate-C4, as well as signal from
acetate-C2. Assignments: 1 Lac-C3; 2 NAA-C6; 3 GABA-C3; 4 Gln-C3; 5 Glu-C3;
6 Gln-C4; 7 Glu-C4; 8 GABA-C2; 9 Asp-C3; 10 Asp-C2; 11 Gln-C2; 12 Glu-C2; 13
Dioxane 14 Lac-C2; 15 Ins-C1-C6; 16 U; 17 U; 18 Glu-C1 and Gln-C1; 19 Gln-C5;
20 Glu-C5 and GABA-C1; 21 Ace-C2; Abbreviations: Ace, Acetate; Asp, aspartate;
GABA, gamma-aminobutyric acid; Lac, lactate; Glu, glutamate; Gln, glutamine; Ins,
inositol; NAA N-acetyl aspartate U, unassigned.
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(Fig. 6d). Comparison of spectra from acutely-treated versus 10-day-ethanol-treated
animals (Fig 6b vs c) suggests that the pattern and magnitude of labeling from [2-13C]
ethanol was similar in these two groups. This impression is borne out in the detailed
analysis of fractional enrichment data for each treatment group (Table 3).
Positive control animals dosed with [2-13C] acetate show highest FE in glutamine
C4, followed by glutamate C4 and GABA C2, and then the carbons labeled during the
second turn (Table 3). This pattern of labeling in brain amino acids is predicted by
our model (Fig. 2), and was found during other studies in which [2-13C] acetate was
administered (Hassel and Sonnewald, 1995; Hassel et al., 1995; Chateil et al., 2001).
The FE of brain amino acids following [2-13C] ethanol administration is consistent with
cerebral metabolism of [2-13C] acetate derived from hepatic oxidation of ethanol. At 15
min post-dose, the most intense labeling is in C4 of glutamine, followed by glutamate
C4, and at later time points, labeling of C2 and C3 of glutamine and glutamate becomes
apparent (Table 4). These data represent the first measurement of brain metabolism
of ethanol-derived acetate using 13C NMR, and provide additional evidence to support
the conclusion that acetate produced from hepatic oxidation of ethanol is a substrate
for brain metabolism.
Comparison of the brain FE values for acutely-dosed animals versus those treated
with ethanol for 10 days and then dosed with [2-13C] ethanol reveals no difference
between the groups, contrary to our hypothesis. Further comparison with the control
groups that received 10 days of water confirms the lack of effect of the 10-day ethanol
treatment on [2-13C] acetate metabolism in brain. The unchanged labeling of brain
metabolites following [2-13C] ethanol administration could be caused by a failure to
increase transport of acetate into brain, or a failure to increase ACoAS activity. The
low FE of brain acetate in the 10 day group suggests that free acetate from serum
(which was 80% enriched in 13C) did not accumulate due to an increase in transport
without an increase in ACoAS activity. Rather, the fact that brain amino acid FE was
statistically equivalent in acutely-treated and 10-day ethanol-treated animals, together
with the low FE of brain acetate, suggests that acetate transport continued to limit
incorporation of 13C into brain amino acids as it did in the control group. Hence we
conclude that transport of acetate into brain did not increase appreciably in response
to 10 days of ethanol treatment. With this finding in mind, we can reconcile our
findings with those of Kiselevski et al. who found that ACoAS activity increased
36% after 7 days of ethanol treatment (Kiselevski et al., 2003) by noting that if the
animals in our study failed to increase acetate transport, we might not find a difference
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Table 4.3: Brain 13C FE of amino acids after dosing with [2-13C] ethanol or acetate.
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x
Pre-Treatment n
Naïve 4* 0.65 ± 0.21 a 0.28 ± 0.10 0.42 ± 0.16 * 0.37
10-day Ethanol 4 0.57 ± 0.04 b 0.33 ± 0.05 0.64 ± 0.10 c 1.28
10-day Water 4 0.54 ± 0.04 b 0.35 ± 0.05 0.45 ± 0.10 0.54
* one sample was excluded as an outlier (GABA C3/C2 = 1.17)
a: marginal significance: p=0.053 via paired t-test (2-tailed) versus ratio in Glutamine
b: p<0.001 via paired t-test (2-tailed) versus C3/C4 ratio in Glutamine
c: p<0.05 2-tailed, t-test, unequal variance versus GABA C3/C2 ratio 
in pooled data from 10-day water and Naïve animals
C3/C4 Glutamate C3/C4 Glutamine C3/C2 GABA
Table 4: carbon-13 labeling ratios in brain amino acids
Table 4.4: 13C labeling ratios in brain amino acids
in 13C incorporation into brain amino acids, even if ACoAS activity did increase. It
is worth noting that the serum acetate levels of 10-day-ethanol-treated animals were
not elevated over acutely-treated and control animals to the extent we expected. An
increase in serum acetate, even in the absence of a decrease in the transporter Km,
would drive entry of additional acetate into the brain, and if activity of ACoAS was
increased also, we might see a corresponding increase of 13C incorporation beyond that
due to high serum acetate alone. Future studies will be required to address this point.
4.3.6 Unequal labeling of Glutamine C2 and C3
One feature of our brain FE data that deviated from our model’s prediction was the
unequal labeling of ”second-turn” carbons. For example, glutamine C2 and C3 are
predicted to have equal FE, as are glutamate C2 and C3, and GABA C3 and C4,
but our data show greater labeling of glutamine and glutamate C2 than C3 (Table 3).
Ours is not the first observation of this phenomenon. Badar-Goffer et al. noted greater
intensity in glutamate C2 versus C3 from guinea pig brain slices incubated with [1-13C]
glucose, and attributed the discrepancy to the formation of doubly-labeled [3,4-2C13]
glutamate which gave a doublet due to carbon-carbon coupling (Badar-Goffer et al.,
1990). These authors state that there is no C2-C3 discrepancy if the satellite resonances
are taken into account. While no value for the size of the apparent discrepancy is
given, from the published spectra it appears that the doubly-labeled species accounts
for ∼10% of the C3-labeled glutamate. Close inspection of our spectra suggests that
while formation of doubly-labeled glutamate may account for the discrepancy in some
90
groups of animals, it cannot explain the discrepancy in others. For example, to explain
the observed glutamine C2-C3 discrepancy in the acutely-treated animals dosed with
[2-13C] acetate on the basis of C3-C4 coupling alone, approximately 50% of C3-labeled
glutamine would have to be doubly-labeled in C4 as well. By peak fitting of the
spectral data for this group, we estimate that of the C3-labeled glutamine, only 13 5%
was doubly labeled, which suggests that another process must be at work. Moreover,
using integral regions that captured satellite peaks for all resonances did not alter the
trends shown in Table 3. Hassel et al. offered a metabolic explanation for greater
labeling in brain glutamate C2 than C3 after [2-13C] acetate dosing: cleavage of citrate
to oxaloacetate by citrate lyase in cytosol (Hassel et al., 1995). This explanation hinged
on the assumption that citrate lyase cleaves a different carbon-carbon bond than the
one formed by citrate synthase. Thus [2-13C] acetate was to have labeled citrate, which
when cleaved by citrate lyase, produced [3-13C] oxaloacetate. However, it appears to be
the prevailing view that citrate synthase and citrate lyase are both highly stereospecific,
and both act on the same bond, so that citrate lyase could not effectively transfer 13C
label from acetate to oxaloacetate (Srere, 1975).
Having discounted previous explanations by investigators who have observed this
phenomenon, we were forced to consider others. One report by Stern et al. indicates the
sterespecificity of pig heart citrate synthase may be as low as 90% (Stern et al., 1966).
If this were true, up to 10% of our label from [2-13C] acetate could have proceeded
directly to the 2C of glutamate and glutamine on the first turn of the TCA cycle. We
implemented a computer simulation incorporating this unexpected flux, and, if present,
it would account for the C2-C3 discrepancy we observed (data not shown). However,
two years after the first report, O’Brien and Stern published a second paper stating that
pig heart citrate synthase is absolutely stereospecific (O’Brien and Stern, 1968), and this
appears to be the currently accepted view (Srere, 1975). Finally, we note reports of so-
called ”channeling” of TCA cycle intermediates (Sumegi et al., 1990) that suggest that
randomization of label through the formation of the symmetrical molecules succinate
and fumarate may be incomplete because these molecules are shuttled between enzymes
rather than diffusing freely. This is an intriguing possibility, and if proven, must be
incorporated into models used to analyze labeling from 13C NMR experiments.
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4.3.7 Steady-state analysis
Based on the serum data which suggest that during the first hour after [2-13C] ethanol
administration acetate concentration and fractional enrichment were relatively con-
stant, we decided to analyze the data from our 60 min time points using a steady-state
analysis. Hassel et al. showed that in the steady state, the C3/C4 ratio in glutamine
and glutamate (and the corresponding C3/C2 ratio in GABA) give an indication of the
fraction of carbon skeletons that exit the TCA cycle on each turn (Hassel et al., 1995).
Further, they noted that the comparison of this ratio in GABA to that in glutamate and
glutamine allows an assessment of the fraction of GABA derived from glutamine carbon
skeletons, versus skeletons from the glutamate pool that have traversed the neuronal
TCA cycle. We found that ratios for the acutely-treated animals and the 10-day water
animals were approximately 0.6 in glutatmate, 0.3 in glutamine, and 0.45 in GABA
(Table 4), consistent with the ratios found by Hassel et al. in [2-13C] acetate-treated
animals. Thus we may conclude that a 1g/kg dose of [2-13C] ethanol does not perturb
the balance between oxidative and synthetic fates for TCA intermediates. In addition,
if we assume that the ratio in GABA reflects synthesis from glutamate skeletons (high
C3/C4 ratio) as well as direct synthesis from glutamine skeletons (low C3/C4 ratio),
we can express this mathematically as an equation of a single variable:
GABAC3/C2 = (x)(GluC3/C4) + (1− x)(GlnC3/C4) (4.4)
where x is the fraction of GABA derived from glutamate. Solving for x, we find that
for acutely-treated animals x=0.38, and for 10-day-water animals x=0.53. In the 10-
day-ethanol group, the C3/C4 ratios for glutamate and glutamine were similar to the
ratios in the acutely-treated animals (Table 4). However, there was a marked increase
in the C3/C2 ratio for GABA. If we calculate x for the 10-day-ethanol group, we find
that GABA is almost exclusively derived from glutamate skeletons, suggesting that
the ethanol treatment reduced synthesis of GABA from glutamine skeletons. Further
studies are required to clarify whether this finding represents altered regulation of
GABA synthesis in response to ethanol exposure.
4.4 Conclusion
The data presented support the conclusion that acetate derived from hepatic oxidation
of ethanol is a substrate for brain metabolism, contributing carbons to glutamate,
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glutamine, and other amino acids. Moreover, under these experimental conditions,
transport of acetate from blood to brain appears to be the factor limiting use in both
acutely treated and ethanol-treated animals. Our data show that 10 days of ethanol
treatment at 5g/kg/day in rats is insufficient to increase cerebral metabolism of ethanol-
derived acetate. Additional studies are required to determine whether it is possible for
prolonged ethanol administration to decrease the Km of the brain monocarboxylate
transporter, allowing greater entry of acetate into brain. We predict that ethanol pre-
treatments that induce large increases in hepatic ethanol oxidizing capacity should
produce greater serum acetate concentrations and increased metabolism of ethanol-
derived acetate due to greater entry of acetate into brain, independent of possible
effects of ethanol on the Km of the transporter.
We have demonstrated that ethanol-derived acetate is a substrate for brain metabolism,
consistent with the notion that ethanol-induced reductions in cerebral glucose utiliza-
tion may reflect cerebral metabolism of ethanol-derived acetate. However, our data
do not establish to what extent, if any, cerebral metabolism of ethanol-derived ac-
etate causes a reduction in glucose utilization. Future studies will be required to clarify
ethanol’s effect on the relative contributions of acetate and glucose to brain metabolism.
While acetate supplies only 5% of the energy in the adult brain (Roach and Resse,
1972), it is important to consider acetate’s significance as a substrate in the context
of normal brain function. The astrocytic TCA cycle contributes 14% to oxidative
metabolism in the brain (Lebon et al., 2002), which suggests that acetate supplies
one third of the energy for astrocytic compartment in the healthy brain. If the use of
acetate during intoxication increased, sudden withdrawal of acetate could jeopardize as-
trocytic support of neuronal function, with profound consequences. The predominant
mechanism for cellular uptake of glutamate in the brain is transport into astrocytes
(Anderson and Swanson, 2000), a process that relies upon sodium and potassium con-
centration gradients. During ischemia these gradients collapse, and the ensuing reversal
of the glutamate transporter on astrocytes accounts for approximately half of the glu-
tamate released into the extracellular space (Phillis et al., 2000). However, transporter
reversal precedes complete collapse of ionic gradients, suggesting that less severe en-
ergy compromise may still produce physiologically significant decreases in glutamate
uptake (Jabaudon et al., 2000). Spanagel et al. showed that increased voluntary alco-
hol consumption in Per2 mutant mice is due to decreased expression of the glutamate
transporter EAAT1 (excitatory amino acid transporter 1; also known as GLAST) on as-
trocytes, leading to increased extracellular glutamate in the ventral striatum (Spanagel
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et al., 2005). This finding supports the concept that craving and relapse may result
from an attempt to decrease anxiety and other symptoms of glutamate-induced hy-
perexcitability by self-medication with ethanol (De Witte, 2004). Moreover, it demon-
strates that astrocytic pathology can itself produce a hyperglutmatergic state with
direct relevance to ethanol consumption.
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Chapter 5
Conclusions and Future Directions
By design, metabolomic studies raise more questions than they answer. With the
exception of Chapter 2, which we believe contains definitive evidence that we have
identified EtG in liver extracts using proton NMR, each result we obtained led us
into new territory. As we had not anticipated that we could measure EtG in liver,
we certainly had no preconceived hypothesis regarding the impact of BHT on EtG
pharmacokinetics. Nonetheless, we developed a hypothesis, and below we propose some
experiments to test it. Similarly, we did not set out to address the impact of ethanol
on gluconeogenesis, but our findings in liver directed us to consider this issue, and
provided enough data for us to propose a hypothesis that explains our results as well
as those of previous investigators. As Christopher Newgard said in a 2005 symposium
on metabolomics, ”We don’t have a hypothesis. We have a philosophy which is that we
need to obtain more data before we can formulate intelligent hypotheses.” The studies
in this dissertation demonstrate the utility of selecting a resonable model organism and
using untargeted analysis to generate focused, testable hypotheses.
5.1 Future Studies on Ethanol and Pyruvate Metabolism
in Liver
As discussed in §3.4.1, the metabolic effect of ethanol on pyruvate metabolism in liver is
quite complex, and different groups have obtained conflicting results in perfused organs,
depending upon which gluconeogenic precursor they supplied in the perfusate. The spe-
cific hypothesis proposed in Fig. 3.12 involves a futile cycle of pyruvate (pyruvate →
oxaloacetate → phosphoenolpyruvate (PEP) → pyruvate). Ignoring for a moment the
experimental details, an ideal test of this hypothesis would be to selectively enrich
hepatic lactate and/or alanine with 13C and then administer ethanol. 13C NMR spec-
troscopy could then determine whether pyruvate, oxaloactate, and phosphoenolpyru-
vate are labeled by carbons from lactate when ethanol is present. The problem is that it
is difficult to label lactate (or alanine) in vivo without also labeling glucose and glyco-
gen, which would make it difficult to distinguish between gluconeogenesis, glycolysis,
and glycogenolysis.
Thus, the best approach may be in use a similar protocol to that employed by
Petersen et al., for the study of futile cycling in hyperthyroid rats (Petersen et al., 1994).
To study the effect of ethanol, we would infuse [3-13C] lactate rather than alanine to
avoid perturbing the regulation of pyruvate kinase (see §3.4.1). Like [3-13C] alanine, [3-
13C] lactate would produce [3-13C] pyruvate, which would produce [3-13C] oxaloacetate
via pyruvate carboxylase. However, due to the rapid exchange between oxaloacetate,
malate and symmetrical fumarate, there will be some randomization of label between
C3 and C2 of oxaloacetate. Thus [2,3-13C] PEP will be formed via PEPCK. If, as we
hypothesize, PK activity is increased when alanine is depleted, [2,3-13C] pyruvate will
result. Thus we may observe futile cycling of pyruvate by measuring enrichment of
pyruvate C2 when co-administering [3-13C] lactate with ethanol. To the extent that
labeling in pyruvate equilibrates with alanine, we may also use enrichment of [2-13C]
alanine as a measure of futile cycling. As Petersen et al. point out, malic enzyme (ME)
can also transfer label from oxaloacetate to pyruvate, but the flux is typically an order
of magnitude less than that via PK.
5.2 Future Studies of Ethanol-Induced Formation
of Ethyl Glucuronide
In Chapter 3, we found that administration of the anti-oxidant BHT reduced the forma-
tion of ethyl glucuronide in the liver during a 4-day binge exposure. We hypothesized
that BHT, though present in small amounts, was a better substrate than ethanol for
glucuronidation. In part, this hypothesis is based on the observation that ”low” doses
of ethanol (10-20mM) do not produce EtG, and even during high doses (∼100mM),
only a tiny fraction of the ethanol is metabolized via this pathway, suggesting that the
reaction is highly unfavorable. One way to test this hypothesis would be to admin-
ister a single dose of ethanol to three groups of animals: controls, BHT-pretreated,
and fluoroquinolone pretreatment + coadministration. Fluoroquinolone antibiotics are
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eliminated via glucuronidation, and (at doses comparable to the BHT doses in Chapter
3) do not appear to induce toxicity when co-administered with ethanol (Olsen et al.,
2006). In addition, since these antibiotics are widely prescribed, especially in alco-
holic patients who present with pneumonia, it would be significant to understand their
impact on the formation of EtG. According to our hypothesis, we would anticipate
that fluoroquinolones would decrease formation of EtG by competing for activated
glucuronide.
It would also be interesting to determine (using GC-MS, which is now commercially
available) the impact of BHT pretreatment on blood and urine EtG over time. It is
possible, of course that BHT actually facilitates transport of EtG out of liver, but that
low sensitivity of our NMR measurements failed to detect an increase in serum EtG.
Either way, it would be interesting to obtain data on the kinetics of EtG elimination
and the effect of BHT on this process.
5.3 Future Studies on Cerebral Metabolism of Ethanol-
Derived Acetate
There are many exciting avenues to pursue with 13C studies of cerebral metabolism and
the effect of ethanol and acetate.
5.4 Cerebral Utilization of Glucose
One specific hypothesis regarding the impact of chronic acetate metabolism in astro-
cytes is as follows: Cronic ethanol exposure may cause flux through pyruvate dehy-
drogenase (PDH) to decrease relative to flux through pyruvate carboxylase (PC). As
shown in Figure 1.3, astrocytes can use acetate to supply acetyl-CoA for the TCA
cycle, diminishing the need for acetyl-CoA to be derived from pyruvate via PDH when
acetate is abundant. It is not certain what effect such a change in the PC:PDH ratio
would have, but we hypothesize that if acetate were suddenly removed, energy failure in
astrocytes could occur, which would impair astrocytic uptake of excitatory glutamate,
perhaps leading to anxiety, or even seizures.
In order to probe the PC:PDH ratio in brain, [2-13C] glucose is an ideal substrate
because it labels different carbons in the 5-carbon pool (glutamate (Glu) and glutamine
(Gln)), depending on whether it is metabolized via PC or PDH. As shown in Figure
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Figure 5.1: [2-13C] glucose is an ideal tracer for studying changes in the PC:PDH ratio.
Flux via PDH directly labels C5 of glutamate and glutamine, whereas flux via PC labels
C3 directly, and C2 due to randomization of label at fumarate. TCA cycling does not
scramble the C5 and the C3 positions, thus enabling an estimate of the PC:PDH ratio
in glutamate, glutamine, GABA, and aspartate.
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Figure 5.2: Expected results using 2-13C glucose to study the effect of chronic ethanol
and acetate exposure on brain metabolism. Abbreviations: ↑, increase; ↓, decrease; ,∆
change; Σ, total; →, causes.
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5.1, the C5 of glutamate is labeled due to flux via PDH, whereas the C2 and C3 are
labeled due to PDH flux.
According to our hypothesis, we expect to find evidence of decreased astrocytic
utilization of pyruvate for synthesis of acetyl-CoA following chronic ethanol exposure
(scenario 1 in Fig. 5.2) due to increased reliance on acetate which is abundant during
ethanol intoxication. In this scenario, we would expect to find an elevation of the
PC:PDH ratio in Gln. To the extent that glial Gln serves as a precursor for Glu and
GABA, the PC:PDH ratio would be elevated in these molecules as well. Since utilization
of pyruvate via PC actually uses 1 molecule of ATP (as opposed to producing 3 ATP if
pyruvate entered the TCA cycle via PDH and exited at -ketoglutarate, or 12 ATP if it
entered via PDH and continued through the cycle), inappropriately high PC activity in
the absence of alternative sources of acetyl-CoA could impair the ability of astrocytes to
maintain the electrochemical gradients required for uptake of glutamate (Anderson and
Swanson, 2000) (scenario 2 in Fig. 5.2). This scenario would be suggested by increased
PC:PDH ratio in Gln, Glu and GABA with decreased total concentration of Gln; to
the extent that the Gln produced by astrocytes continues to serve as a precursor for
Glu, an increase in the PC:PDH ratio for Glu may occur as well. During time course
measurements, we might expect to observe evidence for scenario 1 (decreased flux of
pyruvate through PDH) at early time points, and at later time points this might evolve
into scenario 2 (energy failure due to increased PC:PDH flux). Another anticipated
finding would be increased Gln resulting from astrocytic overproduction during ethanol
intoxication due to an overabundant supply of acetate. If the Gln concentration were
great enough to inhibit the activity of Glutamine synthase, the total FE in Gln, Glu,
and GABA would be reduced, but the concentrations of Glu and GABA would not be
decreased (and might increase) due to the abundance of precursor Gln (scenario 3, Fig.
5.2). A final alternative is the release of unlabeled, preformed Glu from neurons. This
scenario would be characterized by decreased Glu concentration, increased Gln (due
to astrocytic conversion), and a decrease of total FE in Glu, Gln, and GABA since
unlabeled Glu will be entering the metabolic cycle (scenario 4, Fig. 5.2).
5.5 Ethanol-GABA Interactions
It is very tempting to interpret our finding of altered GABA metabolism in 10-day-
ethanol-treated rats as a metabolic manifestation of increased GABA release (Roberto
et al., 2004). However, Roberto et al.’s findings apply to the central amygdala, and not
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necessarily the entire brain. It might be very interesting to combine electrical recordings
of tissue slices with metabolic studies to determine if these effects have a common basis.
As a first pass, it might be possible to simply replace natural abundance glucose in the
perfusate with 13C-labeled glucose, or to supplement the media with natural abundance
(or 13C-labeled) acetate. Then electrical work could proceed as usual, and the tissue
could be extracted afterwards. It might be difficult to obtain NMR signals if the mass of
tissue extracted were less than 100-200mg, but otherwise, given the correct equipment,
NMR analysis should be straightforward.
On a related topic, it occurs to us that some of the results attributed to increased
neuronal release of GABA could perhaps be the result of decreased uptake of GABA
by astrocytes, thus potentitating GABA’s effect. Additional studies would be required
to clarify this point.
5.6 The Future of Metabolomics
Several important challenges must be met in order for the field of metabolomics to
progress from the exploratory phase to a point where significant advances can occur.
In my view, the most important are (i) validation of quantitative methods, (ii) standard-
ization of data collection methods, (iii) standardization of protocols for data analysis,
including the treatment of outlier data, and (iv) formation of public databases into
which results must be entered as a condition of publication in first-tier journals.
Recently, the first steps towards validation of metabolomic methods have been pub-
lished (Dumas et al., 2006), investigating the reproducibility of metabolomic analysis
at sites in Chicago, Japan, and China. The main findings were that 1H NMR-based
metabolomic analysis of urine has a coefficient of variation (CV) of 0 to 10% across
metabolite signals, which is substantially better than pyrolysis metastable atom bom-
bardment time-of-flight mass spectrometry (Py-MAB-TOFMS) that showed 20-250%
CV in the analysis of bovine urine (Dumas et al., 2002), and comparable to the 8% CV
obtained with GC-MS analysis of plant metabolites (Fiehn et al., 2000).
The importance of solid technique in acquiring the data and ”good-faith data min-
ing” are fairly obvious. Unfortunately, neither a coherent set of NMR acquisition pa-
rameters nor a reasonable procedure for multivariate analysis have been widely adopted
thus far. A combination of monte carlo simulations and systematic exploration of in-
strument parameters on actual metabolomic samples will be required.
The rationale for insisting on the formation of a database is as follows: By their
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very nature, metabolomic studies generate ”information overload”, and the design is
inappropriate for journal-only presentation format in which the authors attempt to draw
summary conclusions from the data. Statistical significance in this type of analysis is
an elusive concept (see §3.2.4), and therefore by forming a database in which metabolite
concentrations are stored in meaningful units (e.g. mM for serum or mmol/kg tissue),
new hypotheses, perhaps independent of those that motivated the original work, can be
explored in silico, increasing the value of the original experiments. Also, such a resource
would facilitate the differentiation between shoddy technique and genuine biochemical
differences. In addition, by presenting a consensus view on the properties (e.g. NMR
properties) of various metabolites, the assignment of spectral data can be simplified
and effort can be focused on the characterization of signals due to progressively fewer
”unknown” sources. Similar logic applies to the need to create databases that provide
a biochemical context for various metabolites.
Clinical Metabolomics: the Holy Grail
Thus far, metabolomics has demonstrated great potential, but there are few concrete
examples of successful applications. While the elucidation of biochemical pathways
in plants, cell cultures, or laboratory animals is academically interesting, the greatest
achievement would be to meaningfully improve human health.
A number of areas appear to be on the verge of a major breakthrough. Metabolomic
screening for certain types of cancer might prove lifesaving if early detection can be
translated into increased survival. If it is possible to diagnose coronary artery blockage
by analysis of a blood sample, it might be possible to determine the likelihood that a
younger person will develop heart disease and thereby focus preventative measures on
those at the greatest risk. Metabolomic analysis for staging of certain cancers seems to
be a very sensible and promising approach.
One important limitation in many clinical metabolomic studies is sample size. For
example, in their exciting paper on the metabolomic classification of patients undergo-
ing coronary angiography, Brindle et al. included data from only 66 subjects (Brindle
et al., 2002). In the supplementary material for their paper, the authors argue that
the sample size is ”... certainly large enough: the statistical analysis makes it clear
that the diagnostic power we have demonstrated is very unlikely to be due to chance.”
This argument, while probably correct (i.e. their ability to classify the subjects in their
study was probably not due to random chance), misses the more significant question
of whether within a larger group of subjects additional variance would overwhelm the
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model’s ability to classify based on differences related to risk of heart disease. In par-
ticular, would inclusion of subjects at different sites (where important factors such as
diet and intestinal flora are likely to vary) decrease the predictive power of the ap-
proach? Without being able to provide a definitive negative answer to this question,
the results, while academically interesting, are of little practical value. Larger data
sets, preferably focused on clinically significant diseases, will ensure that the potential
value of metabolomics is realized in the clinic.
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Appendix A
NMR Essentials
I must begin this section with a disclaimer: it is beyond the scope of this dissertation to
provide a complete description of NMR spectroscopy. Rather, the intent is to provide
relevant background for the methods employed in this dissertation. The interested
newcomer is referred to excellent texts by Timothy Claridge or Frank van de Ven.
A.1 History of NMR
Nuclear magnetic resonance has been an extremely fruitful field, the history of which
can be traced by recounting the contributions of the many Nobel laureates who con-
tributed to its development:
• 1943 Otto Stern for discovery of the magnetic moment of the proton
• 1944 Isidor I. Rabi for development of the ”resonance method for recording the
magnetic properties of atomic nuclei”
• 1952 Felix Bloch and Edward M. Purcel ”for their discovery of new methods
for nuclear magnetic precision measurements and discoveries in connection there-
with”
• 1991 Richard R. Ernst for developing high resolution NMR data collection meth-
ods, notably fourier transform NMR and multidimensional NMR
• 2002 Kurt Wutrich for developing methods to determine the three dimensional
structure of biological molecules using NMR
• 2003 Paul C. Lauterbur and Peter Mansfield for developing Magnetic Resonance
Imaging (MRI)
While this is by no means a complete account, it highlights the most important events:
the discovery of the nuclear magnetic moment, the development of technology and
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Type ν (Hz) λ (m) Transition
UV 1016 3× 10−8 Electronic
IR 1013 3× 10−5 Vibrational
NMR 108 3 Nuclear
Table A.1: Comparison of ultraviolet (UV), infrared (IR) and NMR spectroscopy. NMR
spectroscopy uses low energy (long wavelength) EM radiation (radio waves) to probe
the low energy nuclear transitions in a sample.
methods for manipulating and recording signals from nuclear magnetic moments, and
the applications of these techniques to the study of chemistry and medicine.
A.2 NMR as a spectroscopic method
Nuclear magnetic resonance (NMR) spectroscopy (NMRS) shares many similarities
with other forms of spectroscopy, as well as some important differences. Spectroscopy,
by definition, is the study of the interaction of electromagnetic (EM) radiation with
matter (”the sample”). These interactions drive transitions between energy states in
the sample, and the energy difference between the states determines the frequency of
the radiation:
∆E = hν (A.1)
where h is Planck’s constant. For the sake of comparison, the characteristic transitions
and corresponding energies for various forms of spectroscopy are given in TableA.2.
NMR uses very low energy (low frequency, long wavelength) radiation to drive
nuclear transitions.
Certain differences between NMRS and other forms of spectroscopy are worth not-
ing: (i) whereas the molecular energy levels in laser spectroscopy are always available,
the nuclear energy levels that form the basis for NMRS must be induced by placing the
sample in an external magnetic field, (ii) whereas other forms of spectroscopy involve
an interaction with the electric component of the radiation, NMRS involves an inter-
action with the magnetic component, (iii) unlike many other forms of spectroscopy, a
semi-classical description can provide a satisfactory explanation of basic NMRS exper-
iments.
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Nucleus ~I g Natural Abundance (%) NMR frequency
(107rad/T/s) (MHz) @ 2.35T
1H 1/2 26.75 99.985 100
13C 1/2 6.728 1.108 25.14
15N 1/2 -2.713 0.37 10.13
Table A.2: Properties of some isotopes commonly studied by NMR
A.3 Physics of Magnetic Resonance
Though the majority of applications for NMRS are in the fields of chemistry, biochem-
istry, medicine, and other life sciences, the physical basis for the signals involves good
old-fashioned physics: spin, current, magnetic dipoles, vectors, and the like. A solid
understanding of these concepts enables an intuitive approach to experimental design
and analysis, so a brief overview will be presented here.
A.3.1 Nuclear Spin and Nuclear Magnetism
Only certain nuclei exhibit magnetic resonance behavior. Just as electrons can be
stacked into orbitals, and unpaired electrons in metals give rise to paramagnetism,
nucleons (neutrons and protons) within the nucleus that are unpaired give rise to nuclear
spin and a nuclear magnetic dipole moment. Intuitively, a spinning nucleus which bears
a positive charge can be viewed as a tiny circulating current, which produces a magnetic
dipole. The faster the spin, the greater the current, and the greater the resulting
magnetic field. Thus, the nuclear magnetic dipole moment, ~µ, is proportional to the
nuclear spin ~I via a characteristic constant for each nucleus termed the gyromagnetic
ratio, γ:
~µ = γ~I (A.2)
The properties for various commonly-studied isotopes are given in TableA.3.1.
A.3.2 Equation of Motion
Figure A.3.2 depicts a spinning nucleus in an external magnetic field ~B. The equation
of motion is:
d
dt
[~µ] = −γ ~B × ~µ (A.3)
indicating that the force on ~µ is always perpendicular to ~µ, so as to cause precession of
the magnetic moment about the external field.
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Figure A.1: Free precession of a spin in a magnetic field.
The frequency of precession in a static field of magnitude B0 is given by the famous
Larmor equation:
ω0 = γB0 (A.4)
An additional consequence of placing a magnetic dipole in an external field is that there
are only two orientations in which the field exerts no torque on the dipole: when the
dipole is aligned parallel or antiparallel to the field. These are so-called ”spin-up” and
”spin-down” configurations. Intuitively, the parallel ”spin-up” state has a lower energy
than the antiparallel state, and the difference between these states, ∆E, is proportional
to the strength of the external field (as in the Zeeman effect in atomic orbitals).
A.3.3 Equilibrium Magnetization
At thermal equilibrium there is a very slight excess of spins oriented parallel to the
magnetic field, which depends on the strength of the field and the temperature
spin− up
spin− down = e
−∆E
kT (A.5)
k is Boltzman’s constant. In a 100MHz magnet (2.35T) at room temperature (300K),
the population excess in the low energy (spin-up) state is about 10 spins per million.
At first glance, this seems like a hopelessly small number, but one must keep in mind
that a ∼ 1mL NMR sample contains more than 1022 water protons. If we consider the
vector sum of all the ~µ, the bulk magnetization, ~M , things no longer look so bad.
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A.3.4 Relaxation
Without discussing for the moment how we manage to tip the magnetization away
from the external field, it is important to discuss the return to equilibrium. Transverse
relaxation describes the process by which magnetization perpendicular to the external
field decays over time. Longitudinal relaxation describes the regrowth of magnetization
parallel to the external field. In all situations relevant to the work described in this
dissertation, these processes can both be modeled by exponential decay:
M⊥(t) = M⊥(0)e−t/T2 (A.6)
Mz(t) = M0 + (Mz(0)−M0)et/T1 (A.7)
where T1 is the characteristic longitudinal relaxation time, T2 is the characteristic trans-
verse relaxation time, andM0 is the equilibrium magnetization. Physically, the process
of longitudinal relaxation involves exchange of energy between excited nuclei and ”the
lattice”. Transverse relaxation involves the loss of phase coherence due to randomly
timed interactions between neighboring spins (so-called ”spin-spin relaxation”). A far
more detailed description of relaxation mechanisms and their significance can be found
in Vladimir Bakhmutov’s ”Practical NMR Relaxation for Chemists”.
A.4 Modern NMR methods
Early continuous wave (CW) instruments consisted of electromagnets, chart recorders
and/or oscilloscopes, and though certain key experiments were conducted using this
technology, modern instruments are vastly superior.
A.4.1 The Spectrometer
At the heart of the modern NMR spectrometer is a superconducting electromagnet
which must be bathed in liquid helium to maintain its temperature at 4K. In fact, 90%
or so of the bulk of a spectrometer is vacuum-sealed chambers to hold cryogens. As
long as the superconducting coils remain at 4K, they have zero resistance; current is
induced in the magnet once when it is installed, and afterwards it runs indefinitely.
The sample is introduced into an radio frequency (RF) coil inside the magnet, which
allows precisely controlled bursts of RF energy to excite nuclei in the sample. After
the nuclei have been excited by an RF pulse, the same coil can be used to monitor the
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emission signal from the sample.
A.4.2 NMR processing
Time domain data is collected by the instrument and saved in digital form on the
acquisition computer. Fourier transformation yields a frequency domain spectrum,
such as the ones shown in this dissertation.
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Appendix B
Essentials of Metabolism
B.1 Overview of the TCA cycle
The TCA cycle is the central hub of eukaryotic metabolism. The reactions and struc-
tures of the intermediates are shown in Figure B.1.
The logical place to begin describing the cycle is with the substrates that may
enter. Pyruvate (derived from glucose or three carbon metabolites such as lactate or
alanine) may enter the TCA cycle in the oxidative pathway via pyruvate dehydrogenase
(PDH), or via the anapleurotic pathway via pyruvate carboxylase. Many biochemistry
textbooks emphasize only the oxidative pathway. However, if TCA cycle intermediates
are used for net synthesis of other compounds (e.g. α-ketoglutarate is used to produce
glutamate which is exported from the cell), flux through PC is the only way to replenish
intermediates that are lost. Thus the name anapleurosis, derived from Greek: ’filling
up’, is an apt name. Acetate may enter the TCA cycle only as acetyl-CoA via a reaction
catalyzed by acetyl-CoA synthetase (ACoAS).
The citrate synthase (CS) reaction involves the stereospecific condensation of acetyl-
CoA and oxaloacetate to form citrate. Though citrate appears at first glance to be
a symmetrical molecule, it is in fact pro-chiral. The structure of CS determines its
reaction with the asymmetrical substrates
B.2 Metabolite Structures
With hundreds of compounds potentially detectable by NMR, it becomes useful to
have a reference showing the exact chemical structure (with protons drawn explicitly),
together with the trivial name.
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Figure B.1: Reactions of the TCA cycle. Key: Ac, Aconitase; αkD, α-ketoglutarate
Dehydrogenase; CS, citrate synthase; F, Fumarase; IS, Isocitrate dehydrogenase; MD,
Malate Dehydrogenase; PC, pyruvate dehydrogenase; PDH, pyruvate dehydrogenase;
SD, Succinate Dehydrogenase; SS, succinyl-CoA synthetase;
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Table B.1: Metabolite structures
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Appendix C
Mathematical description of
principal components analysis
Mathematically, PCA can be accomplished in the following way. The first step is to
collect the data into matrix form where each row corresponds to an individual, and
each column a parameter measured on that individual.
↔
D=

meas1(I1) meas2(I1) . . . measn(I1)
meas1(I2) meas2(I2) . . . measn(I2)
...
. . .
...
meas1(Im) meas2(Im) . . . measn(Im)
 (C.1)
The next step is to compute the covariance matrix (see §C.1):
↔
C= cov(
↔
D) (C.2)
Finally, we obtain the principal component vectors by computing the eigenvectors
of the covariance matrix
↔
C, and sorting them according to their eigenvalues.
C.1 Covariance and the covariance matrix
The covariance between two random variables X and Y is defined as
Cov(X, Y ) = 〈(X − X¯)(Y − Y¯ )〉 (C.3)
where the angled brackets denote the expected value of the quantity they enclose, and
the bars indicate the means of the random variables. In the case of discrete random
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variables, the formula for computing the covariance is:
Cov(X, Y ) =
1
(n− 1)
N∑
i=1
(xi − x¯)(yi − y¯) = n
∑n
i=1 xiyi −
∑n
i=1 xi
∑n
i=1 yi
n(n− 1) (C.4)
where the n individual elements of X and Y are the xi and yi. The second form is
preferred for computation. Note that Cov(X,X) is equal to the variance of X.
The discussion of covariance has focused thus far only on a single pair of variables.
However for a collection of data organized into a matrix
↔
x of n rows (observations) and
m columns (variables), all possible covariances can be computed in matrix form:
↔
C=

c21 c12 . . . c1m
c21 c
2
2 . . . c2m
...
. . .
...
cm1 cm2 . . . c
2
m
 (C.5)
where the elements cij of
↔
C are given by
cij =
1
(n− 1)
(
n∑
k=1
xikyjk − 1
n
n∑
k=1
xik
n∑
k=1
yjk
)
(C.6)
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